WO1995010513A1 - Benzothiophenes and related compounds as estrogen agonists - Google Patents

Benzothiophenes and related compounds as estrogen agonists Download PDF

Info

Publication number
WO1995010513A1
WO1995010513A1 PCT/IB1994/000282 IB9400282W WO9510513A1 WO 1995010513 A1 WO1995010513 A1 WO 1995010513A1 IB 9400282 W IB9400282 W IB 9400282W WO 9510513 A1 WO9510513 A1 WO 9510513A1
Authority
WO
WIPO (PCT)
Prior art keywords
phenyl
alkyl
hydroxy
compound
group
Prior art date
Application number
PCT/IB1994/000282
Other languages
French (fr)
Inventor
Kimberly O. Cameron
Paul Da Silva-Jardine
Eric R. Larson
James R. Hauske
Robert L. Rosati
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22467873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1995010513(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US08/628,605 priority Critical patent/US6756388B1/en
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to NZ271733A priority patent/NZ271733A/en
Priority to PL94313905A priority patent/PL313905A1/en
Priority to AU75453/94A priority patent/AU7545394A/en
Priority to EP94925597A priority patent/EP0723537A1/en
Priority to BR9407790A priority patent/BR9407790A/en
Priority to JP7511552A priority patent/JPH08511273A/en
Priority to KR1019960701899A priority patent/KR960704874A/en
Publication of WO1995010513A1 publication Critical patent/WO1995010513A1/en
Priority to NO961432A priority patent/NO961432D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/56—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • Estrogen is the agent of choice in preventing osteoporosis or post menopausal bone loss in women; it is the only treatment which unequivocally reduces fractures.
  • estrogen stimulates the uterus and is associated with an increased risk of endometrial cancer. Although the risk of endometrial cancer is thought to be reduced by a concurrent use of a progestogen, there is still concern about possible increased risk of breast cancer with the use of estrogen.
  • This invention provides compounds of the formula
  • R 2 and R 3 are independently
  • R 5 and R 6 are independently C 1 -C 8 alkyl or together form a C 3 -C 10 carbocyclic ring;
  • n 0, 1 or 2;
  • R 11 and R 12 are separately hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, aryl or arylalkyl;
  • n 1 , 2 or 3 and Z 2 is -NH-, -O-, -S- or -CH 2 -.
  • this invention provides a method of treating a mammal having a mammary tumor which comprises administering to said mammal a mammary tumor-inhibiting effective amount of a compound of claim 1.
  • this invention provides a method for the treatment or prevention of diseases or syndromes which are caused by an estrogen deficient state in a mammal which comprises administering to a mammal in need of such treatment or prevention an amount of a compound of claim 1 which is effective in treating said disease or syndrome.
  • C 1 -C 14 alkyl, and C 1 -C 4 alkoxy include groups such as methyl, ethyl, isopropyl, butyl, s-butyl, tetradecyl, undecyl, neopentyl, 2,2-dimethylhexyl, 3-ethylnonyl, 3-butylheptyl, dodecyl, methoxy, propoxy and i-butoxy.
  • Rats Female (S-D) rats 4-6 months of age underwent bilateral ovariectomy or sham surgery and allowed to recover from anesthesia. Rats were s.c. injected with either 10 ⁇ g estradiol or 100 ⁇ g of compound daily for 28 days. All compounds were weighed and dissolved in 10% ethanol in sterile saline. After 28 days the rats were killed and femora removed and defleshed. The femoral were positioned on a Hologic QDR1000W (Hologic, Inc. Waltham, MA) and bone mineral density was determined in the distal portion of the femur at a site from 1 cm to 2cm from the distal end of the femur using the high resolution software supplied by Hologic.
  • Hologic QDR1000W Hologic, Inc. Waltham, MA
  • An in vitro estrogen receptor binding assay which measures the ability of the compounds of the present invention to displace [3H]-estradiol from human estrogen receptor obtained by recombinant methods in yeast, was used to determine the estrogen receptor binding affinity of the compounds of this invention.
  • the materials used in this assay were: (1) Assay buffer, TD-0.3 (containing 10 nM Tris, pH 7.6, 0.3 M potassium chloride and 5 mM DTT, pH 7.6); (2) The radioligand used was [3H]-estradiol obtained from New England Nuclear; (3) the cold ligand used was estradiol obtained from Sigma (4) recombinant human estrogen receptor, hER.
  • each incubate received 50 ul of cold estradiol (nonspecific binding) or the compound solution, 20 uL of the tritiated estradiol and 30 ul of hER solutions. Each plate contained in triplicate total binding and varying concentrations of the compound. The plates were incubated overnight at 4°C.
  • the binding reaction was then terminated by the addition and mixing of 100 mL of 3% hydroxylapatite in 10 mM tris, pH 7.6 and incubation for 15 minutes at 4°C. The mixtures was centrifuged and the pellet washed four times with 1% Triton-X100 in 10 mM Tris, pH 7.6. The hydroxylapatite pellets were suspended in Ecoscint A and radioactivity was assessed using beta scintigraphy. The mean of all triplicate data points (counts per minute, cpm's) as determined.
  • Trifiuoro-methanesulfonic acid 2-(4-methanesulfonyloxy-phenyl)-3-[4- (2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]thiophen-6-yl ester.
  • esters or ethers are frequently administered in the form of pharmaceutically acceptable esters or ethers.
  • the literature concerning such compounds, such as estradiol, provides a great number of instances of such esters and ethers.
  • the compounds of this invention are no exception in this respect, and can be effectively administered as an ether or ester, formed on the hydroxy groups, just as one skilled in pharmaceutical chemistry would expect. While the mechanism has not yet been investigated, it is believed that ethers and esters are metabolically cleaved in the body, and that the actual drug, which such form is administered, is the hydroxy compound itself.
  • ether and ester groups are preferred as constituents of the compounds of this invention.
  • the compounds of formula I may contain ester or ether groups at various portions as defined herein above, where these groups are represented as -COOR 9 , and -OR 10 ;
  • the pharmaceutically acceptable acid addition salts of the compounds of this invention may be formed of the compound itself, or of any of its esters or ethers, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry.
  • salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, maleic acid, acetic acid and propionic acid. It is usually preferred to administer a compound of this invention in the form of an acid addition salt, as it is customary in the administration of pharmaceuticals bearing a basic group such as the pipe
  • the ether is prepared by placing the R 10 moiety on one or more of the hydroxy groups in a manner commonly used for the preparation of ethers.
  • the R 10 group may be added by reaction with appropriate diazo compound, such as diazomethane, phenyldiazomethane or
  • Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
  • a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule.
  • the technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.
  • Scheme 1 illustrates a general route to compounds I.
  • Methyl 4-hydroxybenzoate is alkylated with 1-bromo-2-chloroethane using sodium ethoxide in refluxing ethanol to yield 1-1.
  • Base hydrolysis and treatment with thionyl chloride produced the acid chloride 1-3 which was used crude.
  • the benzothiophene 1-4 prepared as in Journal of Medicinal Chemistry 27, 1984, 1057, was acylated with 1-3 using triflic acid in refluxing methylene chloride to afford the chloride 1-5.
  • Compounds 8c-1-4 can be acylated with an acid chloride to provide 8c-5.
  • Methanesulfonic acid 3-[4-(2-imidazol-1-yl-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester.
  • sodium hydride 0.33 mmol
  • imidazole 0.30 mmol
  • Table 1 lists some of the examples made by these two procedures along with relevant data.
  • Example 13 In a separate flask the product from Step 1 , Example 13 (150 mg, 3.17 mmol) was suspended in 1.2 mL of THF and cooled to -20°C. To this suspension was added the acetic formic anhydride solution (0.088 mL). The reaction was stirred for 2 hrs. then was concentrated to dryness and pumped dry under high vacuum. The crude product was chromatographed in silica gel using 7% MeOH:0.5% NH 4 OH:methylene chloride as the eluant to obtain 65 mg of the title compound.
  • Example 14 N- ⁇ 2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]-thiophen-6-yl ⁇ -methanesulfonamide.
  • the product from Step 1 Example 14 was reacted with methanesulfonyl chloride (1.1 equivalent) in methylene chloride with 1 equivalent of 4-dimethylaminopyridine and 2 equivalents of triethylamine. When finished the reaction was concentrated and chromatographed on silica gel to obtain the title compound.
  • Trifluoro-methanesulfonic acid benzothiazol-6-yl ester To a suspension of 6-Hydroxybenzothiazole (1.00 gm, 6.61 mmol) in 30 mL of methylene chloride,at - 78°C, was added triethylamine (2.76 mL, 19.8 mmol) and 4-dimethylaminopyridine (800mg, 6.5 mmol) then trifluoromethanesulfonic anhydride (1.33 mL, 7.9 mmol). The reaction was allowed to warm to room temperature and stirred for 1 hr. The reaction was then quenched with saturated sodium bicarbonate solution and extracted into methylene chloride.
  • the product from Step 2 (195 mg, 0.46 mmol) was dissolved in 3 mL of methylene chloride and treated with 127 mL of triethylamine and methanesulfonyl chloride (53 mL,

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Benzothiophenes and related compounds of formula (1), wherein A, B, Z are independently -CH=, -CR4= or =N-; X is -S-, -O-, -NH-, -NR2, -CH2-CH2-, -CH2-CH2-CH2-, -CH2-O-; -OCH2-, -CH2-S-, -CO-, -SCH2-, -N=CR2- or -R2C=N-; Y is optionally substituted phenyl, alkyl, cycloalkyl, cycloalkenyl, heterocycle or bicyclic ring system; D is -CO-, -CR2R3-, -CONH-, -NHCO-, -CR2(OH)-, -CONR2, NOR1 CH-NO2 N-CN -NR2-CO-, -C-, -C-, -C-; E is a single bond, optionally substituted phenyl, heterocycle; Z1 is -(CH¿2?)p W(CH2)q-, -O(CH2)p CR5R6- or -O(CH2)p W(CH2)q; G is -NR7R8, (a), (b), (c), a 5- or 6-membered saturated, unsaturated or partially unsaturated and optionally substituted heterocycle or a bicyclic amine containing 5 to 12 carbon atoms either bridged or fused and optionally substituted and R is halogen, -NR2R3, -NHCOR2, -NHSO2R2, -CR2R3OH, -CONR2R3, -SO2NR2R3, OH, -OR1, -O-COR1; are estrogen agonists which are useful for treating syndromes and diseases caused by estrogen deficiency.

Description

BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS This invention relates to estrogen agonists and their pharmaceutical uses.
BACKGROUND OF THE INVENTION
The value of naturally occurring estrogens and synthetic compositions demonstrating "estrogenic" activity has been in their medical and therapeutic uses. A traditional listing of the therapeutic applications for estrogens alone or in combination with other active agents includes: oral contraception; relief for the symptoms of menopause; prevention of threatened or habitual abortion; relief of dysmenorrhea; relief of dysfunctional uterine bleeding; an aid in ovarian
development; treatment of acne; diminution of excessive growth of body hair in women (hirsutism); the prevention of cardiovascular disease; treatment of osteoporosis; treatment of prostatic carcinoma; and suppression of post-partum lactation [Goodman and Gilman, The Pharmacological Basis Of Therapeutics (Seventh Edition) Macmillan Publishing Company, 1985, pages 1421-1423].
Accordingly, there has been increasing interest in finding newly synthesized compositions and new uses for previously known compounds which are
demonstrably estrogenic, this is, able to mimic the action of estrogen in estrogen responsive tissue.
From the viewpoint of pharmacologists interested in developing new drugs useful for the treatment of human diseases and specific pathological conditions, it is most important to procure compounds with some demonstrable estrogen-like function but which are devoid of proliferative side-effects. Exemplifying this latter view, osteoporosis, a disease in which bone becomes increasingly more fragile, is greatly ameliorated by the use of fully active estrogens; however, due to the recognized increased risk of uterine cancer in patients chronically treated with active estrogens, it is not clinically advisable to treat osteoporosis in intact women with fully active estrogens for prolonged periods. Accordingly estrogen agonists are the primary interest and focus.
Osteoporosis is a systemic skeletal disease, characterized by low bone mass and deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. In the U.S., the condition affects more that 25 million people and causes more than 1.3 million fractures each year, including 500,000 spine, 250,000 hip and 240,000 wrist fractures annually. These cost the nation over $10 billion. Hip fractures are the most serious, with 5-20% of patients dying within one year, and over 50% of survivors being incapacitated.
The elderly are at greatest risk of osteoporosis, and the problem is therefore predicted to increase significantly with the aging of the population. Worldwide fracture incidence is forecast to increase three-fold over the next 60 years, and one study estimates that there will be 4.5 million hip fractures worldwide in 2050.
Women are at greater risk of osteoporosis than men. Women experience a sharp acceleration of bone loss during the five years following menopause. Other factors that increase the risk include smoking, alcohol abuse, a sedentary lifestyle and low calcium intake.
Estrogen is the agent of choice in preventing osteoporosis or post menopausal bone loss in women; it is the only treatment which unequivocally reduces fractures. However, estrogen stimulates the uterus and is associated with an increased risk of endometrial cancer. Although the risk of endometrial cancer is thought to be reduced by a concurrent use of a progestogen, there is still concern about possible increased risk of breast cancer with the use of estrogen.
There is a need for improved estrogen agonists which exert selective effects on different tissues in the body. Tamoxifen, 1-(4-β-dimethylaminoethoxyphenyl)-1 ,2-diphenyl-but-1-ene, is an antiestrogen which has a palliative effect on breast cancer, but is reported to have estrogenic activity in the uterus.
Recently it has been reported (Osteoporosis Conference Scrip No. 1812/13 April 16/20, 1993, p29) that raloxifene, 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy) benzoyl] benzo[b] thiophene, mimics the favorable action of estrogen on bone and lipids but, unlike estrogen, has minimal uterine stimulatory effect. (Breast Cancer Res. Treat. 10(1). 1987 p 31-36 Jordan, V.C. et al.)
Raloxifene as well as ethers and esters thereof and related compounds are described as antiestrogen and antiandrogenic materials which are effective in the treatment of certain mammary and prostate cancers. See United States Patent 4,418,068 and Charles D. Jones, et al., J. Med. Chem. 1984, 27, 1057-1066.
Jones, et al in U.S. Patent 4,133,814 describe derivatives of 2-phenyl-3-aroyl-benzothiophene and 2-phenyl-3-aroylbenzothiophene-1-oxides which are useful as antifertility agents as well as suppressing the growth of mammary tumors. Related 2-phenyl-3-aroylbenzothiophenes have also been claimed to modulate the clearance of antibody coated cells from the circulation of mammals, thus providing a method of treating autoimmune disease, U.S. Patent No. 5,075,321.
SUMMARY OF INVENTION
This invention provides compounds of the formula
Figure imgf000005_0001
wherein
A, B and Z are independently
(a) -CH=,
(b) -CR4=,
(c) =N-;
X is
(a) -S-,
(b) -O-,
(c) -NH-,
(d) -NR2-,
(e) -CH2CH2-,
(f) -CH2CH2CH2-,
(g) -CH2O-,
(h) -OCH2-,
(i) -CH2S-,
Figure imgf000005_0002
(k) -SCH2-,
(I) -N=CR2-,
(m) -R2C=N-; Y is
(a) phenyl, optionally substituted with 1 -3 substituents
independently selected from the group consisting of halo, hydroxy, C1-C4 alkyl, C1-C4 alkoxy,
Figure imgf000006_0001
and R1SO2NH-;
(b) C1-C8 alkyl, said alkyl groups being optionally substituted with 1-3 substituents independently selected from the group consisting of -OH,-OR2,
Figure imgf000006_0002
and R1SO2NH-;
(c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from the group consisting of -OH,-R1,
-NH2
Figure imgf000006_0003
and R1SO2NH-;
(d) C1-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from the group consisting of -OH,
-OR1,
Figure imgf000006_0004
and R1SO2NH-;
(e) a five membered heterocycle containing up to two
heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n-, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4
alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1- C4)alkyl,-CO2H, -CN, -CONHOR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1,-NHCOR1, -NO2, and -aryl;
(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n- optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H, -CN, -CONHOR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1,-NHCOR1, -NO2, and -aryl;
(g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n-, optionally substituted with 1 -3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1- C4)alkyl,-CO2H, -CN, -CONHOR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1,-NHCOR1, -NO2, -OH, and -aryl;
D is
(a) -CO-,
(b) -CR2R3-,
(c) -CONH-,
(d) -NHCO-,
(e) -CR2 (OH)-,
(f) -CONR2-,
(g) -NR2CO-,
Figure imgf000007_0001
Figure imgf000007_0002
Figure imgf000007_0003
E is
(a) a single bond; (b) phenyl, or phenyl substituted with up to three substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H, -
CN,-CONHOR, -SO2NHR, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R, -NHCOR1,-NO2, and -aryl; or
(c) a 5 or 6 membered heterocycle, optionally fused to a phenyl ring containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n- optionally substituted with
1 -3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4) alkyl, aryl (C1- C4) alkyl, -CO2H, -CN,-CONHOR, -SO2NHR, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R,-NHCOR1, -NO2, and -aryl;
Z1 is
(a) -(CH2)p W(CH2)q-,
(b) -O(CH2)p CR5 R6-,
(c) -O(CH2)pW(CH2)q;
G is
(a) -NR7 R8,
(b)
Figure imgf000008_0001
wherein n is 0, 1 or 2; m is 1 , 2 or 3; Z2 is -NH- ,-O-,-S-, or - CH2-; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from
(1 ) -OR1,
(2) -SO2NR2R3,
(3)
Figure imgf000009_0001
,
(4) ,
Figure imgf000009_0002
(5) halogen,
(6)
Figure imgf000009_0003
,
(7) ,
Figure imgf000009_0004
(8) ,
Figure imgf000009_0005
(9) ,
Figure imgf000010_0001
(10)
,
Figure imgf000010_0002
(11) ,
Figure imgf000010_0003
(12)
,
Figure imgf000010_0004
(13)-C≡CR1,
Figure imgf000010_0006
Figure imgf000010_0007
Figure imgf000010_0008
(17)
Figure imgf000010_0005
(18) Ar-CH2-,
Figure imgf000011_0001
Figure imgf000011_0002
(21) -(CF2)mCF3 ,
(22)
,
Figure imgf000011_0003
(c)
,
Figure imgf000011_0004
(d) ,
Figure imgf000011_0005
(e) a 5 or 6 membered heterocycle containing up to two
heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n- optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H, -CN, -CONHOR, -SO2NHR, -NH2, C1-C4 alkylamino, C1-C4
dialkylamino, -NHSO2R,-NHCOR1, -NO2,and -aryl; said heterocycle being joined to group Z1 by a carbon to carbon bond or carbon-nitrogen bond;
(f) a bicyclic amine containing a five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4
alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H,-CN,-CONHOR, -SO2NHR, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino,— NHSO2R,-NHCOR1, -NO2, and -aryl;
Z1 and G in combination may be
Figure imgf000012_0001
;
Ar is phenyl or naphthyl optionally substituted with up to three substituents independently selected from R4;
W is
(a) -CH2-,
(b) -CH=CH-,
(c) -O-,
(d) -NR2-,
(e) -S(O)n-,
Figure imgf000012_0002
(g) -CR2(OH)-,
(h) -CONR2-,
(i) -NR2CO-,
(j)
,
Figure imgf000013_0001
(k) -C≡C-;
R is
(a) halogen,
(b) -NR3R2,
(c) -NHCOR2,
(d) -NHSO2R2,
(e) -CR2R3OH,
(f) -CONR2R3,
(g) -SO2NR2R3,
(h) hydroxyl,
(i) R1O-,
Figure imgf000013_0002
R1 is C1-C6 alkyl or phenyl optionally substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
R2 and R3 are independently
(a) hydrogen,
(b) C1-C4 alkyl;
R4 is
(a) hydrogen,
(b) halogen,
(c) C1-C4 alkyl,
(d) C1-C4 alkoxy,
(e) C1-C4 acyloxy,
(f) C1-C4 alkylthio,
(g) C1-C4 alkylsulfinyl, (h) C1-C4 alkylsulfonyl,
(i) hydroxy (C1-C4)alkyl,
(j) aryl (C1-C4)alkyl,
(k) -CO2H,
(I) -CN,
(m) -CONHOR,
(n) -SO2NHR,
(o) -NH2,
(p) C1-C4 alkylamino,
(q) C1-C4 dialkylamino,
(r) -NHSO2R,
(s) -NO2,
(t) -aryl;
R5 and R6 are independently C1-C8 alkyl or together form a C3-C10 carbocyclic ring;
R7 and R8 are independently
(a) phenyl,
(b) a C3-C10 carbocyclic ring, saturated or unsaturated,
(c) a C3-C10 heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-
(d) H,
(e) C1-C6 alkyl,
(f) or form a 3 to 8 membered nitrogen containing ring with R5 or R6; R7 and R8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R7 and R8 may be optionally fused to a phenyl ring;
m is 1 , 2 or 3;
n is 0, 1 or 2;
p is 0, 1 , 2 or 3;
q is 0, 1 , 2, or 3;
and geometric and optical isomers, pharmaceutically acceptable esters, ethers and salts thereof; with the proviso that when A, B and Z are each -CH = , Y is 4-hydroxy phenyl, X is sulfur, D is -CO-, E is 1 ,4-disubstituted phenyl, R is -OH, and Z1 is -OCH2 CH2- then G must be a group other than
Figure imgf000015_0001
, ,
Figure imgf000015_0002
Figure imgf000015_0003
or -N-(C1-C4 alkyl)2; and with the further proviso that if R is
Figure imgf000015_0010
, G must be a group other than ;
Figure imgf000015_0004
and with the further proviso that when A,B and Z are each -CH=, X is S,Y is cycloalkyl or cycloalkenyl; D is
Figure imgf000015_0009
E is 1 ,4 disubstituted phenyl; and Z1 is methylene, O(CH2)m-, ethylene or propylene; G must be other than , or ;
Figure imgf000015_0005
Figure imgf000015_0006
Figure imgf000015_0007
and with the further proviso that when D is -CR2R3- and W is -CO- or -S(O)n-;
G must be other than:
a) -NR11R12 where R11 and R12 are separately hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, aryl or arylalkyl;
b) where n is 0, 1 or 2; m is 1 , 2 or 3; and Z2 is -NH-,
Figure imgf000015_0008
O-, -S- or -CH2-; and with the further proviso that when A, B and Z are each -CH=, Y is 4-hydroxyphenyl, X is -CH2-CH2- or -CH=CH-; D is CO, E is 1 , 4-disubstituted phenyl, and Z1 is -OCH2CH2-; then G must be a group other than or
Figure imgf000016_0001
Figure imgf000016_0002
This invention provides preferred groups of compounds of formula 1 wherein
1. R is -OH;
2. A, B and Z are independently selected from -CH= and -CF=;
3. X is -S-;
4. D is -CO- or CH2-;
5. E is 1 ,4-linked phenyl, pyridyl, pyrimidine, o r
Figure imgf000016_0004
Figure imgf000016_0003
6. Z1 is -OCH2CH2-, -CH2CH2-, -CH2-,
-C≡C-CH2-, or Z in combination with G is
Figure imgf000016_0006
Figure imgf000016_0005
7. G is
Figure imgf000017_0001
8. R is -OH; A, B and Z are -CH-; X is S; Y is
Figure imgf000017_0002
or
Figure imgf000017_0003
D is
Figure imgf000017_0004
or -CH2-,
E is
Figure imgf000017_0005
or
Figure imgf000017_0006
Z1 is -CH2 -CH2-CH2- or
Figure imgf000017_0007
A further preferred group of compounds are those of formula 1 wherein:
A, Band Zare-CH=;
X is -S-;
Y is phenyl, 4-hydroxyphenyl, 4-chlorophenyl, 4-fluorophenyl,
Figure imgf000017_0009
Figure imgf000017_0008
or ; R is -OH-;
D is -CO- or -CH2-;
E is phenyl or pyridyl; and
Z1 is -OCH2CH2-, -C = C-CH2-, -OCH2-, or -NHCH2CH2-.
Further preferred with the above group are those compounds wherein:
G is wherein n is 0, 1 or 2;
Figure imgf000018_0001
m is 1 , 2 or 3 and Z2 is -NH-, -O-, -S- or -CH2-.
Or those compounds wherein G is:
Figure imgf000018_0002
Or those compounds wherein G is:
Figure imgf000018_0003
,
Figure imgf000018_0006
,
or .
Figure imgf000018_0005
Figure imgf000018_0004
In another aspect this invention provides intermediate compounds of the formula
Figure imgf000019_0001
wherein:
J, J1 and J2 are independently -H, -CH3, -SO2CH3 or -SO2CF3; and
L i s -J2 , , -C=C-CH2OJ1 ,
Figure imgf000019_0002
or I ;
Figure imgf000019_0003
with the proviso that only two of J, J1 and J2 may be -H.
In yet another aspect this invention provides a method of treating bone loss associated with estrogen deficiency in a mammal which comprises administering to a mammal in need of such treatment an amount of a compound of claim 1 which is effective in treating said bone loss.
In yet another aspect this invention provides pharmaceutical composition comprising an amount of compound of claim 1 which is effective in treating estrogen deficiency bone loss in a mammal and a pharmaceutically inert carrier.
In yet another aspect this invention provides a method for the treatment or prevention of cardiovascular disease which comprises administering to a mammal in need of such treatment an amount of a compound of claim 1 which is effective in treating or preventing said cardiovascular disease.
In yet another aspect this invention provides a method of treating a mammal having a mammary tumor which comprises administering to said mammal a mammary tumor-inhibiting effective amount of a compound of claim 1. ln yet another aspect this invention provides a method for the treatment or prevention of diseases or syndromes which are caused by an estrogen deficient state in a mammal which comprises administering to a mammal in need of such treatment or prevention an amount of a compound of claim 1 which is effective in treating said disease or syndrome.
DETAILED DESCRIPTION OF THE INVENTION
In this document, all measurements are expressed in weight units, unless otherwise stated, except that ratios of solvents are expressed in volume units.
The general chemical terms used in the formulae above have their usual meanings. For example, the terms C1-C14 alkyl, and C1-C4 alkoxy include groups such as methyl, ethyl, isopropyl, butyl, s-butyl, tetradecyl, undecyl, neopentyl, 2,2-dimethylhexyl, 3-ethylnonyl, 3-butylheptyl, dodecyl, methoxy, propoxy and i-butoxy.
The terms C1-C3 chloroalkyl and C1-C3 fluoroalkyl include methyl, ethyl, propyl and isopropyl substituted to any desired degree with chlorine or fluorine atoms, from one atom to full substitution. The term C5-C7 cycloalkyl includes cyclopentyl, cyclohexyl and cycloheptyl.
Halo means chloro, bromo, iodo and fluoro. Aryl (Ar) includes phenyl and naphthyl optionally substituted with one to three substituents independently selected from R4 as defined above. DTT means dithiothreitol. DMSO means dimethyl sulfoxide. EDTA means ethylene diamine tetra acetic acid.
Estrogen agonists are herein defined as chemical compounds capable of binding to the estrogen receptor sites in mammalian tissue, and mimic the actions of estrogen in one or more tissues.
One of ordinary skill will recognize that certain substituents listed in this invention will be chemically incompatible with one another or with the heteroatoms in the compounds, and will avoid these incompatibilties in selecting compounds of this invention.
The chemist of ordinary skill will recognize that certain compounds of this invention will contain atoms which may be in a particular optical or geometric configuration. All such isomers are included in this invention.
Likewise, the chemist will recognize that various pharmaceutically acceptable esters, ethers and salts may be prepared from certain compounds of this invention. All of such esters, ethers and salts are included in this invention. The compounds of this invention are valuable estrogen agonists and pharmaceutical agents or intermediates thereto. Those which are estrogen agonists are useful for oral contraception; relief for the symptoms of menopause; prevention of threatened or habitual abortion; relief of dysmenorrhea; relief of dysfunctional uterine bleeding; an aid in ovarian development; treatment of acne; diminution of excessive growth of body hair in women (hirsutism); the prevention and treatment of cardiovascular disease; prevention and treatment of atherosclerosis; prevention and treatment of osteoporosis; treatment of prostatic carcinoma; and suppression of post-partum lactation. These agents also have a beneficial effect on plasma lipid levels.
While the compounds of this invention are estrogen agonists in bone, they are also antiestrogens in breast tissue and as such would be useful in the treatment and prevention of breast cancer.
Bone mineral density
Bone mineral density, a measure of bone mineral content, accounts for greater than 80% of a bone's strength. Loss of bone mineral density with age and/or disease reduces a bone's strength and renders it more prone to fracture. Bone mineral content is accurately measured in people and animals by dual x-ray absorptiometry (DEXA) such that changes as little as 1% can be quantified. We have utilized DEXA to evaluate changes in bone mineral density due to estrogen deficiency following ovariectomy (surgical removal of ovaries) and treatment with vehicle, estradiol (E2), keoxifen (raloxifen), or other estrogen agonists. The purpose of these studies was to evaluate the ability of the compounds of this invention to prevent estrogen deficiency bone loss as measured by DEXA.
Female (S-D) rats 4-6 months of age underwent bilateral ovariectomy or sham surgery and allowed to recover from anesthesia. Rats were s.c. injected with either 10μg estradiol or 100μg of compound daily for 28 days. All compounds were weighed and dissolved in 10% ethanol in sterile saline. After 28 days the rats were killed and femora removed and defleshed. The femoral were positioned on a Hologic QDR1000W (Hologic, Inc. Waltham, MA) and bone mineral density was determined in the distal portion of the femur at a site from 1 cm to 2cm from the distal end of the femur using the high resolution software supplied by Hologic.
Bone mineral density is determined by dividing the bone mineral content by the bone area of the distal femur. Each group contained at least 6 animals. Mean bone mineral density was obtained for each animal and statistical differences (p<0.05) from the vehicle-treated ovariectomy and sham-operated group were determined by t test.
In vitro estrogen receptor binding assay
An in vitro estrogen receptor binding assay, which measures the ability of the compounds of the present invention to displace [3H]-estradiol from human estrogen receptor obtained by recombinant methods in yeast, was used to determine the estrogen receptor binding affinity of the compounds of this invention. The materials used in this assay were: (1) Assay buffer, TD-0.3 (containing 10 nM Tris, pH 7.6, 0.3 M potassium chloride and 5 mM DTT, pH 7.6); (2) The radioligand used was [3H]-estradiol obtained from New England Nuclear; (3) the cold ligand used was estradiol obtained from Sigma (4) recombinant human estrogen receptor, hER.
A solution of the compound being tested was made up in TD-0.3 with 4%
DMSO and 16% ethanol. The tritiated estradiol was dissolved in TD-0.3 such that the final concentration in the assay was 5nM. The hER was also diluted with TD-0.3 such that 4-10 μg of total protein was in each assay well. Using microtitre plates, each incubate received 50 ul of cold estradiol (nonspecific binding) or the compound solution, 20 uL of the tritiated estradiol and 30 ul of hER solutions. Each plate contained in triplicate total binding and varying concentrations of the compound. The plates were incubated overnight at 4°C. The binding reaction was then terminated by the addition and mixing of 100 mL of 3% hydroxylapatite in 10 mM tris, pH 7.6 and incubation for 15 minutes at 4°C. The mixtures was centrifuged and the pellet washed four times with 1% Triton-X100 in 10 mM Tris, pH 7.6. The hydroxylapatite pellets were suspended in Ecoscint A and radioactivity was assessed using beta scintigraphy. The mean of all triplicate data points (counts per minute, cpm's) as determined. Specific binding was calculated by subtracting nonspecific cpm's (defined as counts that remain following separation of reaction mixture containing recombinant receptor, radioligand, and excess unlabeled ligand) from total bound cpm's (defined as counts that remain following the separation of reaction mixture containing only recombinant receptor, radioligand). Compound potency was determined by means of IC50 determinations (the concentration of a compound needed to inhibition 50% of the of the total specific tritiated estradiol bound). Specific binding in the presence of varying concentrations of compound was determined and calculated as percent specific binding of total specific radioligand bound. Data were plotted as percent inhibition by compound (linear scale) versus compound concentration (log scale). Compounds of the present invention were found to have IC50 values at or less than 20 μM.
Effect on total cholesterol levels
The effect of the compounds of the present invention on plasma levels of total cholesterol was measured in the following way. Blood samples were collected via cardiac puncture from anesthetized female (S-D) rats 4-6 months of age that were bilaterally ovariectomized and treated with the compound (100/vg/day sc for 28 days or with vehicle for the same time), or sham operated. The blood was placed in a tube containing 30 μL of 5% EDTA (10μL EDTA/1 mL of blood). After centrifugation at 2500 rpm for 10 minutes at 20°C the plasma was removed and stored at -20°C unit assay. The total cholesterol was assayed using a standard enzymatic determination kit from Sigma Diagnostics (Procedure No. 352).
Preferred compounds of the invention include:
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-{4-[2-(4- methyl-piperazin-1-yl)-ethoxy]-phenyl}-methanone;
1-(2-{4-[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophene-3- carbonyl]-phenoxy}-ethyl)-piperidin-4-one;
{4-[2-(Bicyclo[2.2.1]hept-2-ylamino)-ethoxy]-phenyl}-[6-hydroxy-2-(4- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-{4-[2-(6- methyl-2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-methanone;
[4-(2-Cyclopropylamino-ethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy- phenyl)-benzo[b]thiophen-3-yl]-methanone;
{4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-methyl-2- piperidin-1-yl-ethoxy)-phenyl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-methyl- piperidin-2-yl-methoxy)-phenyl]-methanone; [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin- 1-yl-ethoxy)-pyridin-3-yl]-methanone;
[7-Fluoro-6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2- piperidin-1 -yl-ethoxy)-phenyl]-methanone;
[2-(4-Fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1 - yl-ethoxy)-phenyl]-methanone;
{4-[2-(3,4-Dihydro-1 H-isoquinolin-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone;
(2-Benzothiazol-6-yl-6-hydroxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1- yl-ethoxy)-phenyl]-methanone;
[2-(4-Chloro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin- 1-yl-ethoxy)-phenyl]-methanone;
[6-Hydroxy-2-(tetrahydro-pyran-4-yl)-benzo[b]thiophen-3-yl]-[4-(2- piperidin-1-yl-ethoxy)-phenyl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin- 1-yl-ethylamino)-pyridin-3-yl]-methanone;
(6-Hydroxy-2-phenyl-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)- phenyl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin- 1-yl-prop-1-ynyl)-phenyl]-methanone;
2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]- benzo[b]thiophen-6-ol;
[4-(2-Cyclobutylamino-ethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy- phenyl)- benzo[b]thiophen-3-yl]-methanone;
[4-(1-Ethyl-piperidin-2-ylmethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy- phenyl)- benzo[b]thiophen-3-yl]-methanone;
Especially preferred compounds of the invention include:
{4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4- hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin- 1-yl-ethoxy)-pyridin-3-yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-methyl- piperidin-2-yl-methoxy)-phenyl]-methanone; [2-(4-Fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1 - yl-ethoxy)-phenyl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin- 1-yl-prop-1-ynyl)-phenyl]-methanone;
2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]- benzo[b]thiophen-6-ol;
[4-(2-Cyclobutylamino-ethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy- phenyl)- benzo[b]thiophen-3-yl]-methanone;
[4-(1-Ethyl-piperidin-2-ylmethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy- phenyl)- benzo[b]thiophen-3-yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-{4-[2-(6- methyl-2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-methanone;
Intermediate compounds include the following:
[4-(3-Hydroxy-prop-1-ynyl)-phenyl]-[6-methoxy-2-(4-methoxy-phenyl)- benzo[b]thiophen-3-yl]-methanone;
Methanesulfonic acid 3-{4-[6-methoxy-2-(4-methoxy-phenyl)- benzo[b]thiophene-3-carbonyl]-phenyl}-prop-2-ynyl ester;
(4-lodo-phenyl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3- yl]-methanone;
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-(4-(piperidine- 2-ylmethoxy)-phenyl)-methanone;
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-(4-hydroxy- phenyl)-methanone;
3-Bromo-6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophene.
Trifiuoro-methanesulfonic acid 2-(4-methanesulfonyloxy-phenyl)-3-[4- (2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]thiophen-6-yl ester.
Pharmaceutical chemists will easily recognize that physiologically active compounds which have accessible hydroxy groups are frequently administered in the form of pharmaceutically acceptable esters or ethers. The literature concerning such compounds, such as estradiol, provides a great number of instances of such esters and ethers. The compounds of this invention are no exception in this respect, and can be effectively administered as an ether or ester, formed on the hydroxy groups, just as one skilled in pharmaceutical chemistry would expect. While the mechanism has not yet been investigated, it is believed that ethers and esters are metabolically cleaved in the body, and that the actual drug, which such form is administered, is the hydroxy compound itself. It is possible, as has long been known in pharmaceutical chemistry, to adjust the rate or duration of action of the compound by appropriate choices of ester or ether groups. For example, the cycloalkyl ethers are known to increase the duration of action of many hydroxy-group-bearing physiologically active compounds.
Certain ether and ester groups are preferred as constituents of the compounds of this invention. The compounds of formula I may contain ester or ether groups at various portions as defined herein above, where these groups are represented as -COOR9, and -OR10;
R9 is C1-C14 alkyl, C1-C3 chloroalkyl, C1-C3 fluoroalkyl, C5-C7 cycloalkyl, C1-C4 alkoxy, phenyl, or phenyl mono- or disubstituted with C1-C4 alkyl, C1-C4 alkoxy, hydroxy, nitro, chloro, fluoro or tri(clhoro or fluoro)methyl;
R10 is C1-C4 alkyl, C5-C7 cycloalkyl or benzyl; and the pharmaceutically acceptable acid addition salts thereof.
The pharmaceutically acceptable acid addition salts of the compounds of this invention may be formed of the compound itself, or of any of its esters or ethers, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry. For example, salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydriodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, maleic acid, acetic acid and propionic acid. It is usually preferred to administer a compound of this invention in the form of an acid addition salt, as it is customary in the administration of pharmaceuticals bearing a basic group such as the piperidino ring.
When it is desired to prepare a compound of formula 1 of this invention with one or more ether groups, the ether is prepared by placing the R10 moiety on one or more of the hydroxy groups in a manner commonly used for the preparation of ethers. For example, the R10 group may be added by reaction with appropriate diazo compound, such as diazomethane, phenyldiazomethane or
trimethylsilyldiazomethane (see Hashimoto et al., Tet. Let., 4619-22 (1980).) Such reactions are effectively carried out in solvents including esters such as ethyl acetate, haiogenated solvents including dichloromethane and chloroform, and ethers including diethyl ether and tetrahydrofuran. Methanol or boron trifluoride is used as a catalyst, and the process is usually carried out at low temperatures from about -45°C. to about 0°C.
Alternatively, alkylations may be carried out using R10X, where X = Br I, mesylate (-OMs), and a base, sodium hydride or potassium carbonate, for example, in a dipolar aprotic solvent such as dimethylformamide at ambient or elevated temperatures.
It is preferable to prepare monoethers by using an ultimate starting compound in the mono-ether form, and using the ether group as a protecting group through the synthesis, protecting other hydroxy groups with an acyl or sulfonyl group.
When a compound is desired with one or more ester groups, it may often be most convenient to prepare the compound using a protecting group other than the desired ester group, hydrolyze off the protecting group and re-acylate one or both of the hydroxy groups at the end of the synthesis. Such acylations are carried out as described below in the discussion of
Figure imgf000027_0001
groups as protecting groups. A particularly preferred condition for final acylations is to use tetrahydrofuran as the solvent and potassium carbonate as the acid scavenger for acylating agents such as acetic anhydride, benzoyl chloride, ethyl chloroformate and the like.
The compounds of this invention, as discussed above, are very often administered in the form of acid addition salts. The salts are conveniently formed, as is usual in organic chemistry, by reacting the compound of this invention with a suitable acid, such as have been described above. The salts are quickly formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash as the final step of the synthesis. The salt-forming acid is dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the compound of this invention is desired in the free base form, it is isolated from a basic final wash step, according to the usual practice. A preferred technique for preparing hydrochlorides is to dissolve the free base in a suitable solvent and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it.
The dose of a compound of this invention to be administered to a human is rather widely variable and subject to the judgement of the attending physician. It should be noted that it may be necessary to adjust the dose of a compound when it is administered in the form of a salt, such as a laurate, the salt forming moiety of which has an appreciable molecular weight. The general range of effective administration rates of the compounds is from about 0.05 mg/kg/day to about 50 mg/kg/day. A preferred rate range is from about 1 mg/kg/day to 10 mg/kg/day. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day. However, in any given case, the amount of compound administered will depend on such factors as the solubility of the active component, the formulation used and the route of administration.
The route of administration of the compounds of this invention is not critical. The compounds are known to be absorbed from the alimentary tract, and so it is usually preferred to administer a compound orally for reasons of convenience.
However, the compounds may equally effectively be administered percutaneously, or as suppositories for absorption by the rectum, if desired in a given instance.
The compounds of this invention are usually administered as pharmaceutical compositions which are important and novel embodiments of the invention because of the presence of the compounds. All of the usual types of compositions may be used, including tablets, chewable tablets, capsules, solutions, parenteral solutions, troches, suppositories and suspensions. Compositions are formulated to contain a daily dose, or a convenient fraction of daily dose, in a dosage unit, which may be a single tablet or capsule or convenient volume of a liquid.
Any of the compounds may be readily formulated as tablets, capsules and the like; it is preferable to prepare solutions from water-soluble salts, such as the hydrochloride salt.
In general, all of the compositions are prepared according to methods usual in pharmaceutical chemistry. Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline cellulose, sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.
Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
A lubricant is necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
Tablet disintegrators are substances which swell when wetted to break up the tablet and release the compound. They include starches, clays, celluloses, algins and gums. More particularly, corn and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate.
Tablets are often coated with sugar as a flavor and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet. The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art.
When it is desired to administer a compound as a suppository, the typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.
The effect of the compounds may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.
The following typical formulae are provided further to assist the formulations chemist.
CAPSULES
Compound of Formula I 100 mg Microcrystalline cellulose 400 mg
Pregelatinized starch 95 mg
Silicone fluid 2 mg
Compound of Formula I 150 mg Pregelatin starch 106 mg
Starch 52 mg
Silicone fluid 1 .6 mg
Compound of Formula I 150 mg Pregelatinized starch 200 mg
TABLETS
Compound of Formula I 100 mg
Microcrystalline cellulose 240 mg Starch 45 mg
Stearic acid 6 mg
Magnesium stearate 3 mg
Compound of Formula I 150 mg Microcrystalline cellulose 128 mg
Lactose 25 mg Pregelantinized starch 10 mg Stearic acid 8 mg Magnesium stearate 3 mg Colloidal silicon dioxide 2 mg
Compound of Formula I 250 mg Calcium phosphate 58 mg Lactose 54 mg Microcrystalline cellulose 31 mg
GENERAL METHODS FOR THE PREPARATION OF COMPOUNDS OF FORMULA 1 :
The methods described in Part 1 illustrate the synthesis of the estrogen agonists of Formula I.
Part 1
Scheme 1 illustrates a general route to compounds I. Methyl 4-hydroxybenzoate is alkylated with 1-bromo-2-chloroethane using sodium ethoxide in refluxing ethanol to yield 1-1. Base hydrolysis and treatment with thionyl chloride produced the acid chloride 1-3 which was used crude. The benzothiophene 1-4, prepared as in Journal of Medicinal Chemistry 27, 1984, 1057, was acylated with 1-3 using triflic acid in refluxing methylene chloride to afford the chloride 1-5.
Treatment with sodium iodide in refluxing acetone yields the iodide 1-6. Alkylation of various amines with 1-6 is usually carried out either with potassium or cesium carbonate in DMF. Aromatic heterocycles are N-alkylated by 1-6 by first converting them to sodium salts with sodium hydride in DMF. Basic hydrolysis of 1-7 with potassium hydroxide or potassium carbonate afforded compounds of Formula I. Table 1 lists some of the compounds made by this method. Other protecting groups for the phenols like the methyl ether, which can be deprotected with ethanethiol and aluminum trichloride or by boron tribromide, may also be used. The amines were either commercially available or prepared by known routes.
Compound 1-8 is prepared by oxidizing the iodide 1-6 with m-CPBA in methylene chloride followed by basic hydrolysis.
Part 2
The methods described in Part 2 illustrate the preparation of compounds of Formula II. One general approach to some of these compounds is to attach the groups represented by Z to C-3 of a suitably protected benzothiophene 2-1 by Lewis acid catalyzed acylation (Scheme 2). The ketones thus produced can be reduced to the alcohols or methylene analogs 2-3 , 2-4 respectively by lithium aluminum hydride or lithium aluminum hydride-aluminum trichloride for example. Deprotection of 2-2, 2-3, 2-4 affords compounds of general formula II.
Alternately, as illustrated in Scheme 3, a suitably protected benzothiophene 2-1 derivative can be brominated, either with bromine buffered with sodium acetate or N-bromosuccinimide in a chlorinated solvent, to yield 3-1 which can be lithiated by tert-butyllithium in THF at -78° C and quenched with an aldehyde to generate 3-2 which can be oxidized with activated manganese dioxide, for example, and deprotected to afford compounds of Formula II. Compound 3-2 can also be reduced to the methylene compound with sodium borohydride and trifluoroacetic acid, for example.
Scheme 4 illustrates a route to compounds 4-3. Acylation of 2-1 with various chloro or bromo substituted nitrogen containing heterocyclic acid chlorides under aluminum trichloride or other Lewis acids catalysis in methylene chloride or 1 , 2-dichloroethane yields 4-1. By heating 4-1 with various amines, potassium iodide and sodium bicarbonate or sodium alkoxides in polar solvent, like DMF, 4-2 is prepared. Or 4-1 can be reacted with various alcohols under phase transfer conditions, for example, toluene, sodium hydroxide and 18-crown-6, to afford 4-2. Deprotection of 4-2 to yield 4-3 can be achieved by methods known to those skilled in the art.
Acylation of 2-1 with 4-acetoxybenzoyl chloride is achieved with aluminum trichloride in methylene chloride to yield 5a-1 after base hydrolysis of the acetate. (Scheme 5a) A preferred method to synthesize compound 5a-1 is to acylate 2-1 with p-anisoyl chloride then, to selectively demethylate the methoxy group para to the carbonyl group with lithium ethanethiolate in a polar aprotic solvent like dimethyl formamide at 50 through 80°C. Phenol 5a-1 can be alkylated either with bases like potassium carbonate in acetone or dimethyl formamide and various alkyl halides or mesylates or with various alcohols under Mitsonobu conditions (triphenylphosphine and diethydiazodicarboxylate in tetrahydrofuran to yield compounds 5a-2 and, after deprotection 5a-3. Scheme 5b illustrates a general route to compounds of Formula III. The required starting alcohols 5b-1 are commercially available as the free amines or they can be prepared by reduction of the corresponding acid or esters, for example. They may also be available from the amide 5c-1 by organometallic addition followed by reduction and deprotection to 5b-1 (See Scheme 5C).
Mitsonobu coupling to 5a-1 affords 5b-2 which can be debenzylated with hydrogen over Pd/C in alcoholic solvent containing acetic acid to 5b-3. Reductive amination with various aldehydes or ketones leads to 5b-4 then to compounds of Formula III after deprotection.
Iodide 6a-1 , prepared by aluminum trichloride acylation of 2-1 with 4-iodobenzoyl chloride, is a valuable intermediate. (Scheme 6a) Heck reaction of 6a-1 and various olefins affords the trans olefins 6a-2 which can be deprotected to provide 6a-3. A typical set of conditions for the Heck reaction is palladium acetate, tri-ortho-tolylphosphine; tributylamine in N-methypyrrolidinone at temperatures varying from room temperature to 120°C. Hydrogenation of 6a-2 over palladium on carbon affords the saturated analogs 6a-4 which can be deprotected to yield 6a-5. Propargyl alcohol and other acetylenic alcohols can be coupled to 6a-1 with cuprous iodide and bistriphenylphosphine palladiumdichloride in triethylamine at room temperature to give 6a-6, mesylation with methanesulfonyl chloride and a tertiary amine base provides 6a-7. Alkylation of various amines afford 6a-8.
Hydrogenation affords the cis olefins 6a-9, trans-olefins 6a-10 and the saturated compound 6a-5, after deprotection. Vinylation of 6a-1 , Scheme 6b, can be achieved by treatment with vinyltributyltin and bistriphenylphosphine
palladiumdichloride in refluxing dioxane or dimethoxyethane to afford 6b-1.
Oxidative cleavage to the aldehyde 6b-2 can be achieved with catalytic osmium tetroxide and sodium periodate in tert-butanol and water at room temperature.
Reduction with mild reducing agents like sodium borohydride yields the alcohol 6b-3 that can be alkylated by various alkyl halides with bases like sodium hydride in tetrahydrofuran or dimethylformamide to give 6b-4. The reactions illustrated in Scheme 6a and 6b can also be used to prepare the corresponding heterocyclic analogs by starting with 6c-1. Compound 6c-1 can be made by acylating 2-1 with heterocyclic acid chlorides substituted with bromides, iodides or
trifluoromethanesulfonates.
Compound 3-1 can be metallated with tert-butyllithium in an ethereal solvent at low temperatures, usually -78° C, and the resulting 3-lithiobenzothiophene can be quenched with either carbon dioxide or dimethylformamide to yield the acid, 7-1 , or the aldehyde, 7-2, respectively after acid workup. The acid 7-1 can be converted to the Weinreb amide, 7-3, by reaction with N,O-dimethylhydroxylamine and a standard carbodiimide coupling reagent in a chlorinated solvent. The amide 7-3 can be coupled with various Grignard reagents or organolithiums, for example 7-4, to afford the ketones 7-5 after deprotection. The aldehyde 7-2 can be similarly coupled with organometallic reagents to yield 7-5 after oxidation and deprotection.
Part 3
3-Aminobenzenethiol is alkylated on the sulfur by σ-bromo4- methoxyacetophenone in ethanolic potassium hydroxide to yield 8a-1. (Scheme 8a) The amine is acetylated by acetic anhydride, 4-dimethylaminopyridine and pyridine in methylene chloride to afford 8a-2. Dehydrative closure of 8a-2 with
polyphosphoric acid at 80°C affords the benzothiophene 8a-3 which was acylated on treatment with 8a-4 for example (prepared as in Journal of Medicinal Chemistry 1984, 27, 1057) and aluminum trichloride in methylene chloride to afford 8a-5 after demethylation in the same pot with ethanethiol and aluminum trichloride at room temperature. Hydrolysis of 8a-5 with 5N sodium hydroxide in refluxing ethanol affords the useful intermediate amine 8a-6, which can be formylated with formic acetic anhydride in THF to yield 8a-7 or sulfonylated with sulfonyl chlorides to afford the sulfonamides, like the methylsulfonamide 8a-8. Amine 8a-6 can be reacted with other acyl chlorides to form various amides 8a-9 or isocyanates to form carbamates 8a-10 usually with a tertiary amine in methylene chloride.
Scheme 8b outlines the synthesis of 8b-4, a valuable intermediate. As in Scheme 9 using 4-methansulfonyloxy iodobenzene, 8b-1 , can be prepared from 6-methoxybenzothiophene, 9-2. Demethylation using boron tribromide in methylene chloride affords 8b-3 which can be reacted with trifluoromethanesulfonic anhydride and 4-dimethylaminopyridine in methylene chloride to afford the triflate 8b-4.
Palladium catalyzed carbonylation and methanol quench leads to the methyl ester 8b-5 which can be hydrolysed with aqueous base to the acid 8b-6 that can be reacted with various amines and dicyclohexylcarbodiimide to form amides 8b-7. Alternately palladium catalyzed carbonylation in the presence of tributyltin hydride yields the aldehyde 8b-8 which can reduced to the alcohol 8b-9 with mild reducing agents like sodium borohydride. Electrophilic fluorination can be carried out on 2-1 by treating with N-fluorobenzenesulfonamide to yield the corresponding fluoride 8c-1. (Scheme 8c) Alternatively lithiation at the C7 position of the benzothiophene occurs with butyllithium in THF, the resulting anion can be quenched with N-halosuccinimide to yield the corresponding bromide and iodide 8c-2, 8c-3 which are also useful intermediates for palladium catalyzed cross-coupling reactions in an ethereal solvent with various alkenyl, aryl or heteroaryl zinc or trialkyltin reagents, which can be prepared from the corresponding Grignards by treatment with zinc chloride or trialkyltin chloride, to prepare 8c-4. A common palladium catalyst is
tetrakistriphenylphosphine palladium (0). Compounds 8c-1-4 can be acylated with an acid chloride to provide 8c-5.
Part 4
6-methoxybenzothiophene,9a-2, prepared in two steps from 3-methoxybenzenethiol and 2-bromo-1 ,1-diethoxyethane (Scheme 9a), is lithiated with n-butyllithium in THF at 0°C then treated with zinc chloride solution in THF to generate the organozinc reagent that is used immediately in the next step. Cross-coupling between this benzothiophene zinc reagent and alkenyl, aryl or heteroaryl bromides, iodides or triflates is achieved under catalysis by tetrakis
(triphenylphosphine)palladium in THF at room temperature or reflux to afford 9a-3 where R is unsaturated. When R is saturated, Scheme 9a is modified slightly.
Cross-coupling is carried out as above between the benzothipheneorganozinc and enol triflates (prepared from the corresponding ketones with lithium diisopropylamide then N-phenyltrifluoromethanesulfonimide at -78°C in THF) with anhydrous lithium chloride added to give, for example, 9a-5 which is hydrogenated over palladium on carbon to yield 9a-6 Both 9a-3 and 9a-5 can be acylated with an acid chloride, like 8a-4, under Lewis acid catalysis, aluminum trichloride or titanium tetrachloride for example, in methylene chloride or dichloroethane at room temperature or at reflux to afford 9a-4 and 9a-7 after standard demethylation with ethanethiol and aluminum trichloride.
Alternately, compound 9a-4 and 9a-7 can be prepared as in Scheme 3, by brominating 9a-3 with bromine, then metal halogen exchange followed by quench with an appropriate aldehyde, oxidation and deprotection. Alternatively, as in Scheme 9b, 6-methoxybenzothiophene is brominated by N-bromosuccinimide in chloroform at reflux to provide 2-bromo-6-methoxybenzothiophene 9b-1 which can be acylated with acid chlorides like 8a-4 under Lewis acid or triflic acid catalysis in methylene chloride to provide 9b-2. Heck couplings with olefins as described above can provide 2-alkenyl compounds 9b-3 or alkyl 9b-4 after hydrogenation. Alternatively cross-coupling reactions between bromide 9b-2 and aryl or heteroaryl zinc or magnesium reagents catalyzed by palladium (0) catalysts like tetrakis(triphenylphosphine)palladium can provide 2-substituted benzothiophene derivatives 9b-5. Demethylation of 9b-3-5 afford compounds 9b-6.
Scheme 10a describes the synthesis of the indoles 10a-4 . A suitably protected amino phenol is heated to around 170°C with a σ-bromoketone to generate the 2-substituted indole 10-1. This may be N-alkylated by deprotonation with a base like sodium amide in tetrahydrofuran and alkylated with various alkyl halides to yield 10a-2. Both 10a-1 and 10-1 can be acylated with acid chlorides to afford the 3-keto indoles 10a-3 which can be deprotected to the desired indoles 10a-4.
Figure imgf000037_0001
Figure imgf000038_0001
Figure imgf000039_0001
Figure imgf000040_0001
Figure imgf000041_0001
Figure imgf000042_0001
Figure imgf000043_0001
Figure imgf000044_0001
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
EXAMPLES
1 H-NMR spectra were recorded on a Bruker AC250 spectrometer. Reactions were usually performed under a nitrogen atmosphere. Anhydrous solvents were purchased from Aldrich Chemical Company and were used as received.
Tetrahydrofuran (THF) was distilled from sodium / benzophenone prior to use. Commercially available reagents were used as received unless otherwise noted. Thin layer chromatography was performed on E. Merck Kieselgel 60 F254 plates (0.25 mm) and flash column chromatography was performed using EM Science Silica Gel 60. Chromatography solvent mixtures are reported as volume ratios. Compounds of general Formula I are made by the reactions outlined in Scheme 1 herein above. Synthesis of the key intermediate methanesulfonic acid 3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester, then a general procedure to compounds of Formula I is described.
Example 1
Step 1
4-(2-Chloro-ethoxy)-benzoic acid methyl ester. To 35 mL of ethanol was added sodium pellets (2.27gm, 98.6 mmol). After all the sodium had disappeared methyl-4-hydroxybenzoate (15 gm, 98 mmol) was added in one portion at room temperature. The reaction mixture was then heated to 60°C and treated dropwise with 1 -bromo-2-chloroethane (10.2 gm, 123 mmol) in 15 mL of ethanol. The reaction was stirred for 16 hrs then cooled to room temperature and concentrated. The residue was taken up in ethyl acetate and washed with water, 2N NaOH, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using 1 : 10 Ethyl acetate: Hexanes to 1 :6 Ethyl acetate: Hexanes as the gradient eluant to yield 11.9 gm of the title compound.
Step 2
4-(2-Chloro-ethoxy)benzoic acid. To methyl 4-(2-Chloroethoxy)-benzoic acid (11.8 gm, 53.5 mmol) dissolved in 118 mL of methanol was added 2N KOH (35mL, 1.3 equiv.) and the resulting solution was heated at 50°C for 24 hrs. The reaction was cooled to room temperature and the methanol evaporated off. The residue was diluted with water and extracted once with ethyl acetate. The aqueous layer was then acidified with 6N HCI and a precipitate formed which was filtered off, washed well with water, and pumped dry under vacuum to yield 10 gm of the title compound.
Step 3
Methanesulfonic acid 3-[4-(2-chloro-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. The product from step 2 (654mg, 3.26 mmol) was stirred with thionyl chloride (1.2 mL) for 3 hrs at 50° C. Then the excess thionyl chloride was removed by vacuum distillation. Azeotroping with benzene removed any residual thionyl chloride. The residue was dissolved in methylene chloride (29 mL) and methanesulfonic acid 2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester 1 (1 gm, 2.5 mmol) and triflic acid (0.78 mL) were added. The reaction was stirred at reflux overnight. The reaction was not complete therefore another equivalent of acid chloride was added and the reaction stirred a further 3 hours until complete. The mixture was cooled 10 0°C and saturated sodium bicarbonate solution was added slowly. The organic layer was separated and washed once with water, dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using 1 :1 Ether: Petroleum Ether to 7:1 Ether: Petroleum Ether as the gradient eluant to yield 886 mg of the title compound.
1. Journal of Medicinal Chemistry, 1984, 27, 1057.
Step 4
Methanesulfonic acid 3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. A solution of the product from step 3 (3.5 gm, 1 equiv.) and Nal ( 9.02 gm, 10 equiv.) in 50 mL of Acetone was heated at reflux for 2 days until the reaction was complete. The reaction was cooled and concentrated to a solid. The residue was dissolved in ethyl acetate, washed with water and brine, dried over anhydrous magnesium sulfate, filtered, and concentrated to yield 3.5 gm of the title compound.
General Procedure to alkylate primary and secondary amines with
methanesulfonic acid 3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl )-benzo[b]thiophen-6-yl ester (the product from step 4) followed by base hydrolysis to yield compounds of Formula I. An example is given using 2-Aza-bicyclo[2.2.1] heptane as the amine. Step 5
Methanesulfonic acid 3-{4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-benzoyl}-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. A solution of the product from step 4 (3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester) (0.26 mmol), 2-Aza-bicyclo[2.2.1] heptane (0.28 mmol), and either potassium carbonate or cesium carbonate (0.7 mmol) as the base in 5 mL of DMF was stirred at room temperature for 16 hrs. The reaction was then concentrated and the residue was taken up in ethyl acetate, washed with water, and brine. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated to yield 111 mg of the title compound. This can be used crude in the hydrolysis step or preferably purified by silica gel chromatography.
Step 6
{4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. A solution of the product from Step 5 (111 mg, 0.17 mmol) and potassium carbonate (7.5 equiv.) in 10 mL of methanol was heated at 50°C for 48 hrs. The mixture was concentrated to a solid. This solid was chromatographed on silica gel using 1% MeOH / methylene chloride to 20% MeOH / methylene chloride as the gradient eluant to yield the desired product which was then made into the its hydrochloride salt with hydrogen chloride in dioxane.
Alternatively, the product from Step 5 can be hydrolysed by refluxing with 250 mL 5N sodium hydroxide in 5 mL of ethanol for one hour. The reaction is acidified with 3 N HCI to about pH5 then saturated sodium bicarbonate is added and the whole extracted with chloroform (about half volume of methanol is added if necessary to dissolve the organics). The organic layer is washed with brine and dried over anhydrous sodium sulfate. After concentration and silica gel
chromatography, usually with 2-7% methanol in methylene chloride with 1-5% ammonium hydroxide if needed, the product is obtained as a foam. This is converted to the HCI salt as above.
When the nitrogen being alkylated is contained in a heterocycle the reaction is performed as below with imidazole being used as the example. Example 2
Step 1
Methanesulfonic acid 3-[4-(2-imidazol-1-yl-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. To mixture of sodium hydride (0.33 mmol) in 10 mL of dimethylformamide was added imidazole (0.30 mmol) and stirred at room temperature for 15 min. To this mixture was added (3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester) (0.22 mmol), and the reaction was stirred at room temperature for 16 hrs. It was concentrated and the residue was taken up in ethyl acetate and washed with water. The organic layer was then washed with brine, dried over Anhydrous magnesium sulfate, filtered, and concentrated to yield the title compound.
Step 2
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-imidazol-1-yl-ethoxy)-phenyl]-methanone. The mesylate protecting groups on the product from Stepi were removed by base hydrolysis using either potassium carbonate in methanol or sodium hydroxide in ethanol as in Step 6 of Example 1 to yield the title compound.
1H NMR (MeOH-d4) δ 7.75(m, 3H), 7.45(d, 1 H), 7.29(d, 1 H), 7.20(d, 1 H), 7.18(d, 2H), 7.00(s, 1 H), 6.85(m, 3H), 6.60(d, 2H), 4.40(t, 2H), 4.30(t, 2H)
Table 1 lists some of the examples made by these two procedures along with relevant data.
Example 3
Step i
Methanesulfonic acid 3-[4-(2-hydroxy-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. A solution of (3-[4-(2-iodo-ethoxy)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester) (0.03 mmol) and m-chloroperoxybenzoic acid (0.036 mmol) in 5 mL of methylene chloride was stirred at room temperature for 16 hrs. at which time an additional 0.036 mmol of M-Chloroperoxybenzoic acid was added and the reaction heated to 50°C for 16 hrs. The reaction was extracted into methylene chloride from saturated sodium bicarbonate solution. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated to yield the title compound. Step 2
[4-(2-Hydroxy-ethoxy)-phenyl]-6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]-thiophen-3-yl]-methanone. The mesylate protecting groups on the title compound from Step 1 were removed using the methods outlined in Example 1 , Step 6 to obtain the title compound.
Mass Spectroscope: M+ = 406
Tlc: Rf =0.50 ( 9:1 Chloroform / Methanol)
Example 4
Step 1
4-(1-Methyl-2-piperidin-1-yl-ethoxy)-benzoic acid methyl ester. To a solution of methyl-4-hydroxy benzoate (13 mmol) and α-methyl-1-piperidine ethanol (13 mmol) in 40 mL of tetrahydrofuran was added triphenylphosphine (16.9 mmol). At 0°C, DEAD (diethyl azodicarboxylate) (15.6 mmol) was added dropwise. After the addition was complete, the reaction was allowed to warm to room temperature and stirred for 1 hr. The reaction was then concentrated to dryness and the residue was taken up in EtOAc, and the product was extracted into 1 N hydrochloric acid. The aqueous layer was made basic with 5N NaOH and extracted three times with EtOAc. The combined organics were then washed with brine, dried over MgSO4, filtered, and concentrated. Chromatography on silica gel using 30% THF / hexanes afforded two isomeric products the title compound and 4-(2-piperidin-1-yl-propoxy)-benzoic acid methyl ester.
Step 2
4-(1-Methyl-2-piperidin-1-yl-ethoxy)-benzoic acid. A solution of 4-(1-Methyl-2-piperidin-1-yl-ethoxy)-benzoic acid methyl ester, from Step 1 , Example 4, (0.69 g, 2.49 mmol) and 1.5 mL of 2N NaOH in 2 mL of methanol was heated to reflux for 2 hrs. The reaction mixture was then diluted with water and washed with ethyl acetate to remove any by-products. The aqueous layer was concentrated to dryness and chromatographed on a reverse phase silica column using 20% MeOH in 80% Buffer (0.1% TFA in water) as the eluant to yield the title compound as its trifluoroacetate salt.
Step 3
4-(1-Methyl-2-piperidin-1-yl-ethoxy)-benzoyl chloride. To a solution of the product from Step 2, Example 4 (2.07 mmol) in 27 mL of chlorobenzene was added 3 drops of dimethylformamide and thionyl chloride (35.1 mmol) and the solution was heated to 75°C for 2.5 hrs. The reaction was then cooled to room temperature and the excess thionyl chloride and chlorobenzene was removed in vacuo. Theoretical yield was assumed and the residue was dissolved in 6.16 mL of dichloromethane (i.e., 1 mL of solution = 100 mg of the title compound). The solution was used in the next step of the synthesis without further purification.
Step 4
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-4-(1-methyl-2-piperidin-1-yl-ethoxy)-phenyl]-methanone. To a dichloromethane solution of the title compound from Step 3 (3.33 mmol) was added 35 mL of dichloromethane, 6-methoxy-2-(4-methoxyphenyl)-benzo[b]thiophene (1 g, 3.7 mmol), and AICI3 (3.7 g, 27.8 mmol) and the resulting mixture was stirred for 2 hrs. at room temperature. Demethylation was accomplished by adding ethanethiol (1.06 mL, 14.4 mmol) and stirring for a further hour. The reaction was quenched with saturated sodium bicarbonate solution and extracted with chloroform containing enough methanol (about 3 / 1 chloroform-methanol)to dissolve the organics. If needed the aluminum salts can be filtered off through a Celite pad prior to separation of the layers. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. Filtration, concentration and chromatography on silica gel using 5% methanol in dichloromethane as the eluant afforded the title compound
(800 mg) as a yellow foam. The title (360 mg) was converted to the hydrochloride salt by dissolving in 500 mL-1 mL of dioxane and adding a solution of hydrogen chloride in dioxane. The solid that precipitates is filtered off and washed with ether to yield the hydrochloride salt of the title compound as a tan solid.
1H NMR (MeOD) δ 7.70(d, 2H), 7.45(d, 1 H), 7.25(d, 1 H), 7.15(d, 2H), 6.85(m, 3H), 6.60(d, 2H), 3.75(t, 1 H), 2.65(m, 1 H), 2.50(m, 5H), 1.60(m, 4H), 1.45(m, 2H), 1.20(d, 3H)
Example 5
Step 1
(6-Chloro-pyridin-3-yl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. To a suspension of 2-Chloropyridine-5-carbonyl chloride (4.23 gm, 24 mmol) and 6-Methoxy-2-(4-methoxy-phenyl)- benzo[b]thiophene (5.0 gm, 18.5 mmol) in 275 mL of methylene chloride was added aluminum trichloride (18.5g, 138.8 mmol) in three portions. The black-red reaction was stirred for 16 hrs. at room temperature. The reaction was then quenched with 400 mL of 2N NaOH (slowly and cooled in ice) and extracted into 300 mL of methylene chloride. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated to a yellow solid which was
chromatographed on silica gel using 5% to 20% Ethyl acetate / Hexanes as the gradient eluant to yield 2.47 gm of the title compound.
Step 2
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanone. A solution of the product from Step 1 , Example 5 (250 mg, 0.61 mmol), sodium bicarbonate (66.7 mg, 0.79 mmol), potassium iodide (50.7 mg, 0.31 mmol), and 1-Pyrrolidin-2-ylmethyl-piperidine2 (308 mg, 1.83 mmol) in 3 mL of Ethanol was heated at reflux for 16 hrs. The solvent was evaporated off and the residue was diluted with water and extracted with methylene chloride. The organics were dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was chromatographed on silica gel using 3% MeOH : 2% aqueous NH4OH : 95% methylene chloride as the eluant to obtain 261 mg of the title compound.
2. Journal of Medicinal Chemistry 1992, 35, 4334
Step 3
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin-1-yl-ethylamino)-pyridin-3-yl]-methanone. To a solution of the product from Step 2, Example 5 (230 mg, 0.42 mmol) in 3 mL of methylene chloride at 0°C was added dropwise boron tribromide (2mL, 1 mM in CH2CI2, 2 mmol). The reaction was allowed to warm to room temperature and stirred for 2 hrs. The reaction was quenched with saturated sodium bicarbonate solution and extracted three times with chloroform. The combined organic layer was dried over sodium sulfate and concentrated to a yellow solid which was then chromatographed on silica gel using 1% MeOH:1% NH4OH: 98% methylene chloride to 3% MeOH:1 % NH4OH: 96% methylene chloride as the gradient eluant to yield 67 mg of the title compound.
1H NMR (MeOH-d4) δ 8.25(s, 1 H), 7.85(s, 1 H), 7.50(d, 1 H), 7.25(m, 3H), 6.95(dd, 1 H), 6.70(d, 2H), 6.45(d, 1 H), 3.50(t, 2H), 2.55(m, 6H), 1.55(m, 6H) Example 6
Step 1
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-{6-[2-(piperidine-1-carbonyl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanone. The coupling of the product from Stepi , Example 5 (6-Chloro-pyridin-3-yl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone) and piperidin-1-yl-pyrrolidin-2-yl-methanone 2 was accomplished by the procedure set forth in Example 5, Step 2 to afford the title compound.
Step 2
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-{6-[2-(piperidine- 1-carbonyl)-pyrrolidin-1-yl]-pyridin-3-yl}-methanone. Demethylation of the product from Step 1 , Example 6 was carried out as in Example 5, Step 3 to yield the title compound.
1H NMR (MeOH-d4) δ 8.25(d, 1 H), 7.85(d, 1 H), 7.30(d, 1 H), 7.20(m, 3H), 6.85(d, 1 H), 6.60(d, 2H), 6.40(bs, 1 H)
Example 7
Step 1
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin-1-yl-ethylamino)-pyridin-3-yl]-methanone. The coupling of the product from Step 1 , Example 5 (6-Chloro-pyridin-3-yl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone) and 1-(2-Aminoethyl)-piperidine was carried out as in Example 5, Step 2 to give the title compound.
Step 2
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin-1-ylmethyl-pyrrolidin-1-yl)-pyridin-3-yl]-methanone. Demethylation of the product from Step 1 , Example 7 was carried out using the procedure in Example 5, Step 3 to obtain the title compound.
1H NMR (MeOH-d4) δ 8.25(s, 1 H), 7.85(d, 1 H), 7.45(d, 1 H), 7.20(m, 3H), 6.85(dd, 1 H), 6.65(d, 2H), 6.45(d, 1 H), 3.50(m, 1 H), 3.35(d, 2H), 2.45(m, 6H), 2.00(m, 4H), 1.50(m, 6H) Example 8
Step 1
[6-(2-piperidinyl-1-yl-ethoxy)-pyridin-3-yl]-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. The coupling of the product from Step 1 , Example 5 (6-Chloro-pyridin-3-yl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone) and 1-piperidineethanol sodium salt was carried out as in Example 5, Step 2 to yield the title compound.
A preferred method is to use phase transfer conditions. The product from Step 1 , Example 5 (6-Chloro-pyridin-3-yl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone) (890 mg, 2.17 mmol), 1-piperidineethanol (365 mg, 2.8 mmol), potassium hydroxide (256 mg, 4.56 mmol, crushed in a mortar), 18-crown-6 (57mg, 0.2 mmol) in 20 mL of toluene was stirred overnight at room temperature. The reaction was diluted with ethyl acetate and washed with water. The organic layer was washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The residue was chromatographed on silica gel using 1 :1 ethyl acetate to pure ethyl acetate as the gradient eluant to yield 920 mg of the title compound.
Step 2
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[6-(2-piperidin-1-yl-ethoxy)-pyridin-3-yl]-methanone. The methyl protecting groups on the product from Step 1 , Example 8 were removed by the procedure in Example 5, Step 3 to obtain the title compound.
1H NMR (MeOH-d4) δ 8.35(s, 1 H), 8.05(d, 1 H), 7.60(d, 1 H), 7.30(d, 1 H), 7.20(d, 2H), 6.95(d, 1 H), 6.80(d, 1 H), 6.65(d, 2H), 4.65(t, 2H), 3.45(t, 2H), 3.20(m, 4H), 1.80(m, 6H)
Example 9
Step 1
Methanesulfonic acid 3-[4-(2-bromo-ethyl)-benzoyl]-2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester. A flask with 4-(2-Bromo-ethyl)-benzoic acid (190 mg) and thionyl chloride (0.5 mL) was heated to 50°C for 3 hrs. The excess thionyl chloride was removed in vacuo.
Methanesulfonic acid 2-(4-methanesulfonyloxy-phenyl)-benzo[b]thiophen-6-yl ester (290 mg) dissolved in 8 mL of methylene chloride was added to the residue along with triflic Acid (0.23 mL). The reaction was stirred at reflux for 16 hrs. The reaction mixture then was poured into cold sodium bicarbonate solution and the organic layer was separated, dried over anhydrous sodium sulfate, filtered, and
concentrated. The crude product was chromatographed on silica gel using 1 :10 Ethyl acetate / Hexanes to 2:3 Ethyl acetate / Hexanes as the gradient eluant to yield 174 mg of the title compound.
Step 2
Methanesulfonic acid 2-(4-methanesulfonyloxy-phenyl)-3-[4-(2-pyrrolidin-1-yl-ester)-benzoyl]-benzo[b]thiophen-6-yl ester . A solution of the product from Step 1 , Example 9 (87 mg, 0.14 mmol) and pyrrolidine (100 mL) in 0.5 mL of Ethanol was heated to reflux for 16 hrs. The ethanol was evaporated off and the residue was diluted with water and extracted with methylene chloride. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using 5% diethylamine / ethyl acetate as the eluant to obtain 38 mg of the title compound.
Step 3
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-pyrrolidin-1-yl-ethyl)-phenyl]-methanone. A solution of the product from Step 2, Example 9 (30 mg, 0.05mmol) and 5N NaOH (0.076 mL) in 1.5 mL of ethanol was heated to reflux for 4 hrs. The solvent was stripped off and the residue was diluted with water and washed with ether. The aqueous layer was then acidified with 1 N HCI, then the solution was adjusted to pH 9 with sodium bicarbonate solution at which time a precipitate was formed. The product was filtered off to give 18.3 mg of the title compound.
1H NMR (DMSO-d6) d 7.60(d, 2H), 7.35(d, 1 H), 7.25(m, 3H), 7.15(d, 2H), 6.85(dd, 1 H), 6.65(d, 2H), 2.75(bt, 2H), 2.40(m, 6H), 1.65(m, 4H)
Example 10
Step 1
Acetic acid 4-chlorocarbonyl-phenyl ester. A solution of 4-acetoxybenzoic acid (200mg, 1.11 mmol), thionyl chloride(1.6 mL), 1 drop of DMF, and 7.5 mL of chlorobenzene was heated to 80°C for 1.5 hrs. The reaction was then cooled to room temperature and the solvent and excess thionyl chloride were removed in vacuo. Theoretical yield of the title compound was assumed and the residue was used as is.
Step 2
Methanesulfonic acid 4-[3-(4-hydroxy-benzoyl)-6-methanesulfonyloxy-benzo[b]thiophen-2-yl]-phenyl ester. To a solution of methanesulfonic acid 4-(6-methanesulfonyloxy-benzo[b]thiophen-2-yl)-phenyl ester1 (200 mg, 0.5mmol) in 14 mL of methylene chloride was added the product from Step 1 , Example 10 (104 mg, 0.53mmol) and triflic acid (0.47 mL, 5.3mmol). The reaction was stirred at reflux for 16 hrs, cooled to room temperature, and poured into saturated sodium bicarbonate solution and was extracted into methylene chloride. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated. The residue was purified by silica gel chromatography using 20% Ethyl acetate /
Hexanes to 50% Ethyl acetate / Hexanes as the gradient eluant to obtain 125 mg of the title compound.
Step 3
Methanesulfonic acid 4-{6-methanesulfonloxy-3-[4-(1-methyl-piperidin-2-ylmethoxy)-benzoyl]-benzo[b]thiophen-2-yl}-phenyl ester. A solution of the product from Step 2, Example 10 (115 mg, 0.22mmol), (1-methyl-piperidin-2-yl)-methanol (28.7 mg, 0.22 mmol), and triphenylphosphine (75 mg, 0.29 mmol) in 3 mL of THF was cooled to 0°C and diethyl azodicarboxylate (0.051 mL , 0.26 mmol) was added dropwise. After the addition was complete, the reaction was allowed to warm to room temperature and was stirred for 16 hrs. The THF was evaporated off and the residue was chromatographed on silica gel using 1% MeOH - 1%
Diethylamine-methylene chloride as the eluant to give 80 mg of the title compound. Step 4
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-methyl-piperidin-3-ylmethoxy)-phenyl]-methanone. A solution of the product from Step 3, Example 10 (80 mg, 0.13 mmol) and 0.25 mL of 5N NaOH in 8 ml of ethanol was heated to reflux for 1 hr. The solvent was evaporated and the residue was diluted with water. The reaction was acidified with 3N HCI then made basic with saturated sodium bicarbonate solution. This aqueous solution was extracted with 1 :2 MeOH / methylene chloride. The combined organic layers were dried over anhydrous magnesium sulfate, filtered, and concentrated. The crude product was
chromatographed on silica gel using 5% MeOH / CHCI3 to 10% MeOH / CHCI3 as the gradient eluant to obtain the title compound.
1H NMR (MeOH-d4)δ 7.70(d, 2H), 7.40(d, 1 H), 7.25(d, 1 H), 7.15(d, 2H), 6.85(m, 3H), 6.60(d, 2H), 4.05(m, 2H), 2.95(m, 1 H), 2.35(s, 3H), 2.30(m, 2H), 1.65(m, 6H).
Example 11
Step 1
Methanesufonic acid 4-{6-methansulfonyloxy-3-[4-(pyridin-2-ylmethoxy)-benzoyl]-benzo[b]thiophen-2-yl}-phenyl ester. The coupling of the product from Step 2, Example 10 (Methanesulfonic acid 4-[3-(4-hydroxy-benzoyl)-6-methanesulfonyloxy-benzo[b]thiophen-2-yl]-phenyl ester) and pyridin-2-yl-methanol was accomplished by using the procedure outlined in Example 10, Step 3 except stirring for 1 hour instead of 16 hours at room temperature. The solvent was evaporated off and the crude product was chromatographed on silica gel using 1 % MeOH / methylene chloride to 2% MeOH / methylene chloride as the gradient eluant to yield the title compound.
Step 2
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(pyridin-2-yl-methoxy)-phenyl]-methanone. The mesylate protecting groups on the product from Step 1 , Example 11 were removed as in Example 10, Step 4 to obtain the title compound.
1H NMR (DMSO-d6) δ 8.55(d, 1 H), 7.80(t, 1 H), 7.65(d, 2H), 7.50(d, 1 H), 7.35(m, 2H), 7.25(d, 1 H), 7.15(d, 2H), 7.00(d, 2H), 6.85(dd, 1 H), 6.65(d, 2H)
Example 12
Step 1
2-(4-Amino-phenylsulfanyl)-1-(4-methoxy-phenyl)-ethanone. To a mixture of 84 mL of ethanol and 33 mL of water was added 4.48 gm of potassium hydroxide and the mixture was stirred until all the potassium hydroxide was in solution. To this mixture was added 3-aminothiophenol (10.00 gm, 79.9 mmol) in one portion. The reaction was cooled to 5°C and a solution of 2-bromo-4-methoxyacetophenone (18.0 gm, 79.9 mmol) in 30 mL of ethyl acetate was slowly added. The reaction was stirred vigorously for 1 hr. keeping the temperature below 23°C. The solvent was evaporated off and the residue was back extracted into ethyl acetate from water. The aqueous layer was extracted with ethyl acetate. The combined organic layers were then dried over anhydrous magnesium sulfate, filtered, and concentrated. The solid residue was recrystallized from ethanol to yield 16.9 gm of the title compound. Step 2
N-{4-[2-(4-Methoxy-phenyl)-2-oxo-ethylsufanyl]-phenyl}-acetamide. A solution of the product from Step 1 , Example 12 (2.00 gm, 7.33 mmol), pyridine (1.78 mL, 21.9 mmol), 4-dimethylaminopyridine (859 mg, 7.33 mmol) and acetic anhydride (0.83 mL, 8.79 mmol) in 9 mL of methylene chloride was stirred at room temperature for 2 hrs. The reaction was diluted with methylene chloride and washed with water, 1 N HCI, and water again. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was recrystallized from ethyl acetate to obtain 1.17 gm of the title compound.
Step 3
N-[2-(4-Methoxy-phenyl)-benzo[b]thiophen-6-yl]-acetamide. A flask containing polyphosphoric acid (6.4 gm) was heated on a steam bath to 90°C and to this was added the product from Step 2, Example 12 (1.17 gm, 3.73 mmol) portionwise. The reaction mixture turned black and was stirred at 90°C for 4.5 hrs. The reaction was then cooled to about 70°C and poured into vigorously stirring ice-water mixture. The crude product precipitated out and was collected by vacuum filtration, washing well with water. The material was pumped dry under vacuum and was slurried in refluxing acetone for 1 hr., cooled, filtered, washed with acetone, and pumped dry to yield the title compound.
Step 4
N-{2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzo yl]-benzo[b]thiophen-6-yl}-acetamide. To a solution of the product from Step 3, Example 12 (1.8 gm, 6.08 mmol) and 4-(2-piperidin-1-yl-ethoxy)-benzoyl chloride1 (7.29 mmol) in 65 mL of methylene chloride was added, in three portions, aluminum trichloride (6.08 gm, 46 mmol) keeping the internal temperature at 28°C. The reaction was stirred at this temperature for 3 hrs. Acylation was complete, then the methyl protecting group was removed by the dropwise addition of ethanethiol (2.0 mL, 26.7 mmol) and stirring for 3 hrs at room temperature. The reaction was then cooled to 0°C and was quenched by dropwise addition of 41 mL of THF, 20% HCI (6.66 mL), and 41 mL of water keeping the temperature around 5°C. A gummy solid was produced after the reaction was quenched which was then filtered from the solvents. The solids were dissolved in MeOH, diluted with Ethyl acetate, and washed with saturated sodium bicarbonate solution. A precipitate formed and was removed by filtration. The filtrate layers were separated and the aqueous layer was extracted again with ethyl acetate. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. Alternatively the reaction can be quenched with saturated sodium bicarbonate solution followed by extraction with a mixture of 2 : 1 chloroform-methanol. The aluminum salts are filtered off through a pad of Celite then the layers of the filtrate are separated. The aqueous layer is extracted with chloroform-methanol. The combined organic layers is washed with brine, dried over anhydrous magnesium sulfate, filtered and concentrated. The crude material was chromatographed on silica gel using 5% MeOH: methylene chloride as the eluant to obtain 500 mg of the title compound.
1H NMR (MeOH-d4) δ 8.45(d, 1 H), 7.75(d, 2H), 7.60(d, 1 H), 7.40(dd, 1 H),
7.25(d, 2H), 6.90(d, 2H), 6.65(d, 2H), 4.15(t, 2H), 2.85(t, 2H), 2.60(m, 4H), 2.20(s, 3H), 1.65(m, 4H), 1.50(m, 2H)
Example 13
Step 1
[6-Amino-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. A solution of the product from Step 4, Example 12 (400 mg, 0.78 mmol) and 2.4 mL of 5N NaOH in 24 mL of ethanol was stirred at reflux for 48 hrs. The ethanol was evaporated off and the residue was diluted with water and acidified with 1 N HCI to pH3. The aqueous solution was then made basic with saturated sodium bicarbonate solution. A solid precipitated and was filtered to yield the title compound.
1H NMR (MeOH-d4) δ 7.75(d, 2H), 7.35(d, 1 H), 7.20(m, 3H), 6.90(d, 2H), 6.85(dd, 1H), 6.60(d, 2H), 4.20(t, 2H), 2.95(t, 2H), 2.70(m, 4H), 1.70(m, 4H), 1.55(m, 2H)
Example 14
Step 1
N-{2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]-thiophen-6-yl}-formamide. Formic acid (0.18 mL, 4.57 mmol) was added dropwise to a flask containing acetic anhydride ( 0.36 mL, 3.84 mmol) at 0°C. The mixture was then heated for 2 hrs. at 50°C. At this time the mixture was cooled to room temperature and 0.29 mL of THF was added. In a separate flask the product from Step 1 , Example 13 (150 mg, 3.17 mmol) was suspended in 1.2 mL of THF and cooled to -20°C. To this suspension was added the acetic formic anhydride solution (0.088 mL). The reaction was stirred for 2 hrs. then was concentrated to dryness and pumped dry under high vacuum. The crude product was chromatographed in silica gel using 7% MeOH:0.5% NH4OH:methylene chloride as the eluant to obtain 65 mg of the title compound.
1H NMR (MeOH-d4) δ 8.45(s, 1 H), 8.40(s, 1 H), 7.75(d, 2H), 7.60(d, 1 H),
7.40(dd, 1 H), 7.25(d, 2H), 6.90(d, 2H), 6.70(d, 2H), 4.15(t, 2H), 2.80(t, 2H), 2.55(m, 4H), 1.65(m, 4H), 1.50(m, 2H)
Example 15
Step 1
N-{2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzoyl]-benzo[b]-thiophen-6-yl}-methanesulfonamide. The product from Step 1 , Example 14 was reacted with methanesulfonyl chloride (1.1 equivalent) in methylene chloride with 1 equivalent of 4-dimethylaminopyridine and 2 equivalents of triethylamine. When finished the reaction was concentrated and chromatographed on silica gel to obtain the title compound.
1H NMR (MeOH-d4) δ 7.90(d, 1 H), 7.75(d, 2H), 7.60(d, 1 H), 7.25(m, 3H), 6.90(d, 2H), 6.65(d, 2H), 4.20(t, 2H), 3.05(s, 3H), 2.95(t, 2H), 2.70(m, 4H), 1.70-(m, 4H), 1.55(m, 2H)
Example 16
Step 1
1-(2,2-Diethoxy-ethylsulfanyl)-3-methoxy-benzene. To a solution of 3-methoxybenzenethiol (15.0 mL, 120 mmol) and potassium carbonate (16.6 gm, 120 mmol) in 150 mL of acetone at room temperature was added dropwise 2-bromo-1 ,1-diethoxy-ethane (16.5 mL, 110 mmol). The reaction mixture was stirred at room temperature for 16 hours. The solids in the reaction mixture were removed by filtration and were washed well with acetone. The filtrate was concentrated. The residue was diluted with water and extracted several times with ether. The ether layers were combined and washed with 0.5 M KOH, water, brine, and were then dried over anhydrous sodium sulfate, filtered, and concentrated to yield 28.2 gm of the title compound.
Step 2
6-Methoxy-benzo[b]thiophene. To a solution of boron trifluoride etherate (14.45 mL, 115 mmol) in 2000 mL of methylene chloride stirring in a cold water bath 20°C was added dropwise 1-(2,2-Diethoxy-ethylsulfanyl)-3-methoxy-benzene (28.2 gm, 110 mmol) dissolved in 500 mL of methylene chloride. The addition was complete in 3 hrs. and then the reaction was warmed to room temperature for a further 1.5 hrs. The reaction mixture was then quenched with saturated sodium bicarbonate solution. The organic layer was separated and the aqueous layer was back extracted several times with methylene chloride. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel (using a gravity column) using hexanes as the eluant to yield 10.9 gm of the title compound.
GENERAL PROCEDURE FOR THE SYNTHESIS OF COMPOUNDS OF FORMULA IV:
The general scheme is outlined in Scheme 8b. Three sets of conditions are used for the acylation step and they are described below. Table 2 lists the compounds with relevant data and which procedure was used in each case.
Step 3
6-Methoxy-2-phenyl-benzo[b]thiophene. To a solution of 6-Methoxy-benzo[b]thiophene (250 mg, 1.52 mmol) in 3.7 mL THF at -20°C was added dropwise n-butyllithium (0.67 mL, 1.67 mmol). The mixture was stirred at 0°C for 1.5 hrs. and at room temperature for 0.5 hrs. Anhydrous zinc chloride (269 mg, 1.97 mmol) in 1.9 mL of THF was added by cannula to the reaction. The reaction was then stirred at room temperature for 15 minutes and then Pd(Ph3P)4 (70 mg, 0.06 mmol) and iodobenzene (0.22 mL, 1.97 mmol) were added and the reaction stirred at room temperature for 3 hrs. Other aromatic or heteroaromatic bromides, iodides or triflates can replace iodobenzene in this procedure. If a triflate is used 3 equivalents of anhydrous lithium chloride must be added. The reaction can be refluxed overnight to push it towards completion. The solvent was evaporated and the residue was diluted water and extracted into ethyl acetate. The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using 100% Hexanes to 1% ethyl acetate / hexanes as the gradient eluant to yield 250 mg of the title compound. ACYLATION PROCEDURE A
Step 4
(6-Hydroxy-2-phenyl-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. A solution of the product from Step 3, Example 16 (272 mg, 1.13 mmol), 4-(2-Piperidin-1-yl-ethoxy)-benzoyl chloride1 (7.9 mL, 1.53 mmol), and titanium tetrachloride (6.62 mL, 5.66 mmol) in 16.5 mL of methylene chloride was stirred at room temperature for 6 hrs. To demethylate, ethanethiol (0.335 mL, 4.53 mmol) and AICI3 (600 mg, 4.53 mmol) in two portions were added to the reaction and it was stirred for an additional 2.5 hrs. The reaction was quenched with saturated sodium bicarbonate solution and the solution was extracted twice with methylene chloride. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was
chromatographed on silica gel using 1% MeOH : CH2CI2 to 5% MeOH : CH2CI2 as the gradient eluant to obtain 231 mg of the title compound.
1H NMR (MeOH-d4)δ 7.70(d, 2H), 7.40(m, 3H), 7.30(d, 1 H), 7.25(m, 3H), 6.90(d, I H), 6.85(d, 2H), 4.15(t, 2H), 2.75(t, 2H), 2.55(m, 4H), 1.60(m, 4H), 1.50(m, 2H)
Example 17
Step 1
2-(4-Fluoro-phenyl)-6-methoxy-benzo[b]thiophene. The reaction of (250 mg, 1.52 mmol) and 4-Fluoroiodobenzene (0.228 mL, 1.5 mmol) was performed as in Example 16, Step 3. The crude product was chromatographed on silica gel using Hexanes as the eluant to give 280 mg of the title compound.
ACYLATION PROCEDURE B
Step 2
{2-(4-Fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. To a solution of the product from Example 17, Step 1 (83 mg, 0.32 mmol) and 4-(2-Piperidin-1-yl-ethoxy)-benzoyl chloride (1.39 mL, 0.39 mmol) in 3.3 mL of 1 ,2-dichloroethane was added, in two portions, aluminum trichloride (322 mg, 2.4 mmol) and the reaction was heated at reflux for 1 hr. At this time the coupling was complete and demethylation was carried out cooling the reaction to room temperature, adding ethanethiol (0.10 mL, 1.41 mmol) dropwise and stirring at room temperature for a further 1.5 hrs. The reaction was quenched with saturated sodium bicarbonate solution and extracted twice with methylene chloride. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material was chromatographed on silica gel using 1% MeOH : methylene chloride to 3% MeOH:methylene chloride as the gradient eluant to yield the title compound.
1H NMR (MeOH-d4) δ 7.75(d, 2H), 7.45(m, 3H), 7.35(d, 1 H), 7.05(d, 2H), 6.95(dd, 1 H), 6.90(d, 2H), 4.20(t, 2H), 2.80(t, 3H), 2.60(m, 4H), 1.65(m, 4H), 1.50(m, 2H)
Example 18
Step 1
Trifluoro-methanesulfonic acid benzothiazol-6-yl ester. To a suspension of 6-Hydroxybenzothiazole (1.00 gm, 6.61 mmol) in 30 mL of methylene chloride,at - 78°C, was added triethylamine (2.76 mL, 19.8 mmol) and 4-dimethylaminopyridine (800mg, 6.5 mmol) then trifluoromethanesulfonic anhydride (1.33 mL, 7.9 mmol). The reaction was allowed to warm to room temperature and stirred for 1 hr. The reaction was then quenched with saturated sodium bicarbonate solution and extracted into methylene chloride. The organics were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using 1 :10 Ethyl acetate / Hexanes to 1 :4 Ethyl acetate / Hexanes as the gradient eluant to yield 1.41 gm of the title compound. Step 2
6-(6-Methoxy-benzo[b]thiophen-2-yl)-benzothiazole. A solution of 6-methoxybenzo[b]thiophene (300 mg, 1.82 mmol) in 5 mL of THF was cooled to - 20°C and 2.5 M n-BuLi (0.8 mL, 2.01 mmol) was added dropwise. The reaction was stirred at 0°C for 0.5 hrs and then warmed to room temperature for an additional 0.5 hrs. Next a 0.5 M solution of anhydrous zinc chloride in THF (4.75 mL, 2.38 mmol) was added and the reaction was stirred at room temperature for 15 minutes followed by the addition of anhydrous lithium chloride (3 equivalents), tetrakis-triphenylphosphine palladium (84 mg, 0.073 mmol) and, by cannula, the product from Example 18, Step 1 (505 mg, 2.01 mmol) dissolved in 2 mL of THF. The reaction was stirred at room temperature for 16 hrs. The THF was removed and the residue diluted in water and extracted three times with Ethyl acetate. The combined organics were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude material was chromatographed on silica gel using 1 :20 THF / Hexanes to 1 :10 THF / Hexanes as the gradient eluant to yield the title compound.
ACYLATION PROCEDURE C
Step 3
(2-Benzothiazol-6-yl-6-hydroxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. To a solution of the product from Example 18, Step 2 (63 mg, 0.21 mmol) and 4-(2-Piperidin-1-yl-ethoxy)-benzoyl chloride (1.38 mL, 0.25 mmol) in 1 mL of methylene chloride was added AICI3 (212 mg, 1.6 mmol) and the reaction was stirred at room temperature for 3 hrs. When acylation was complete, to demethylate, ethanethiol (0.069 mL, 0.93 mmol) was added dropwise and the reaction stirred for a further 1.5 hrs. The reaction was cooled to 0°C and quenched with saturated sodium bicarbonate solution. The organic layer was separated and the aqueous layer was extracted with 10% MeOH / methylene chloride. The organic layers were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using 2% MeOH / methylene chloride to 4% MeOH / methylene chloride as the gradient eluant to obtain the title product.
1H NMR (MeOH-d4) δ 9.20(s, 1 H), 8.10(s, 1 H), 7.90(d, 1 H), 7.70(d, 2H),
7.55(d, 1 H), 7.50(d, 1 H), 7.30(d, 1 H), 6.95(d, 1H), 6.80(d, 2H), 4.10(t, 2H), 2.70(t, 2H), 2.50(m, 4H), 1.60(m, 4H), 1.45(m, 2H)
Example 19
Step 1
2-Cyclohex-1-enyl-6-methoxy-benzo[b]thiophene. To a solution of 6-methoxybenzo[b]thiophene (362 mg, 2.21 mmol) in 5.5 mL of THF at -20°C was added dropwise 2.5 M nBuLi (0.97 mL, 2.4 mmol) and the reaction was stirred at 0°C for 40 minutes and was then warmed to room temperature for 30 minutes.
Next, ZnCI2 (390 mg, 2.87 mmol) in 2.5 mL of THF was added by cannula and the reaction was stirred at room temperature for 15 minutes. At this point, Pd(Ph3P)4 (102 mg), trifluoromethanesulfonic acid cyclohex-1-enyl ester (0.6 gm, 2.93 mmol) 3 and anhydrous lithium chloride (0.28 gm, 6.63 mmol) were added and then the reaction mixture was stirred for 16 hrs. at room temperature. The tetrahydrofuran was removed in vacuo and the residue diluted with water and extracted with ethyl acetate. The combined organic layers was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was chromatographed on silica gel using hexanes as the eluant to yield 368 mg of the title compound.
3. Tetrahedron Letters 1983, Vol 24, 979
Step 2
2-Cyclohexyl-6-methoxy-benzo[b]thiophene. The product from
Example 19, Step 1 (264 mg) and 10% Palladium on Carbon (60 mg) in 30 mL of ethyl acetate was added to a Parr shaker flask and hydrogenated at 50 psi for 16 hrs. at room temperature. The mixture was filtered over celite and concentrated. The crude product was chromatographed on silica gel using Hexanes as the eluant to give 210 mg of the title compound.
Step 3
(2-Cyclohexyl-6-hydroxy-benzo[b]thiophen-3-yl)-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone. The product from Example 19, Step 2 and 4-(2-Piperidin-1-yl-ethoxy)-benzoyl chloride were coupled according to procedure C above and the methyl protecting group removed using etanethiol / aluminum trichloride to yield the title compound.
1H NMR (MeOH-d4) δ 7.85(d, 2H), 7.25(d, 1 H), 7.15(d, 1 H), 7.10(d, 2H), 6.80(d, 1 H), 4.25(t, 2H), 2.85(t, 2H), 2.65(m, 4H), 2.00(m, 2H), 1.65(m, 12H), 1.30(m, 3H).
Example 20
Step 1
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-(4-methoxy-phenyl)-methanone. To a suspension of 6-methoxy-2-(4-methoxyphenyl)-benzo[b]thiophene (2 g, 7.4 mmol), and p-anisoyl chloride in 110 mL of methylene chloride was added aluminum trichloride (4.93 g, 37 mmol) in three portions and the reaction was stirred overnight. It was then quenched with 200 mL of 2N sodium hydroxide and extracted with methylene chloride. The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography using 15% ethyl acetate - hexanes as eluant the title compound (1.73 g) was obtained. Step 2
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-(4-hydroxy-phenyl)-methanone. To a solution of ethanethiol (538mL, 7.27 mmol) in1.8 mL of tetrahydrofuran, cooled to -30°C was added n-butyllithium (2.57 mL, 2.5M,
6.42 mmol) and the reaction was warmed to room temperature. Dimethylformamide (1 mL) was added then the product from Stepi (1.73 g, 4.3 mmol) in 2.7 mL of dimethylformamide. The reaction was heated at 58°C for two hours then at 80°C for 1 hour. The cooled reaction was poured into 33 mL oh 1 N hydrochloric acid and extracted with ethyl acetate. The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography using 15% ethyl acetate -hexanes as eluant the title compound (1.17 g) was obtained.
1H NMR (CDCI3) δ 7.7 (d, 2H), 7.55 (d, 1 H), 7.36 (d, 2H), 7.31 (d, 1 H), 6.95 (dd, 1 H), 6.76 (d, 2H), 6.68 (d, 2H), 3.9 (s, 3H), 3.75 (s, 3H)
Step 3
[4-(1-Benzyl-piperidine-2-ylmethoxy)-phenyl]-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. The product from Step 2 (600 mg) was coupled with (1-benzyl-piperidin-2-yl)-methanol (379 mg) as is Example 10, Step 3 to yield the title compound (320 mg) after silica gel chromatography with 10% ethyl acetate / hexanes to 20% ethyl acetate / hexanes as the gradient eluant. Step 4
[4-(1-Benzyl-piperidine-2-ylmethoxy)-phenyl]-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. The product from Step 3 (295 mg, 0.5 mmol) was combined with boron tribromide (2.50 mL, 1M in dichloromethane, 2.5 mmol) in 4 mL of methylene chloride at room temperature. After 2 hours the reaction was quenched with saturated sodium bicarbonate solution and extracted into chloroform-methanol (10 : 1). The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography with 40% ethyl acetate-hexanes as eluant the title compound (169 mg) was obtained.
Step 5
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-(4-(piperidine-2-ylmethoxy)-phenyl)-methanone. The product from Step 4 (165 mg) was dissolved in 25 mL of ethanol and 6 mL of acetic acid and hydrogenated at 50 psi with 100 mg of 10% palladium on carbon as catalyst for 3 hours. The catalyst was removed by filtration through a pad of Celite and the filtrate was concentrated. The acetic acid was removed by azeotroping with heptane. The product was purified by silica gel chromatography with 5% methanol-methylene chloride as eluant.
1H-NMR (MeOH-d4) δ 7.66 (d, 2H), 7.4 (d, 1 H), 7.25 (d, 1 H), 7.1 (d, 2H), 6.8 (dd, 1 H), 6.78 (d, 2H), 6.6 (d, 2H)3.9 (dd, 1 H), 3.75 (dd, 1 H), 3.1 (bd, 1 H), 2.95 (m, 1 H), 2.6 (m, 1 H), 1.2-1.9 (m)
Step 6
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-ethyl-piperidin-3-ylmethoxy)-phenyl]-methanone. The product from Step 5 (19 mg, 0.04 mmol) was combined with acetaldehyde (10 mL), sodium cyanoborohydride (4 mg, 0.062 mmol) in 200 mL of methanol and the whole was stirred at room temperature overnight. The reaction was diluted with water and extracted with 2:1 methylene chloride / methanol. The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography with 5% methanol-methylene chloride-2% aqueous ammonium hydroxide as eluant the title compound (3 mg) was obtained.
1H NMR (MeOH-d4) δ 7.7 (d, 2H), 7.4 (d, 1 H), 7.25 (d, 1 H), 7.15 (d, 2H), 6.35 (dd, 1 H), 6.3 (d, 2H), 6.6 (d, 2H), 4.05 (d, 2H), 1.06 (t, 3H)
Example 21
Step 1
(4-lodo-phenyl)-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-methanone. To a suspension of 6-methoxy-2-(4-methoxyphenyl)-benzo[b]thiophene (3g, 11.1 mmol), and p-iodobenzoyl chloride in 65 mL of methylene chloride was added aluminum trichloride (2.1 g) in three portions and the reaction was stirred 3 hours. It was then poured into ice-water and extracted with methylene chloride. The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column
chromatography with 3% ethyl acetate-hexanes as eluant the title compound (3.97 g) was obtained.
1H-NMR (CDCI3) δ 7.6 (d, 2H), 7.6 (d, 1 H), 7.45 (d, 2H), 7.32 (d, 1 H), 7.0 (dd, 1 H), 6.78 (d, 2H), 3.9 (s, 3H), 3.78 (s, 3H) Step 2
[4-(3-Hydroxy-prop-1-ynyl)-phenyl]-[6-methoxy-2-(4-methoxy-phenyl)-benzofb]- thiophen-3-yl]-methanone. The product from Step 1 (214 mg,
0.43 mmol) was combined with triethylamine (35 mL), copper (I) iodide (0.4 mg), propargyl alcohol (50mL, 0.86 mmol), bis-triphenylphosphine palladium dichloride at room temperature. The copper iodide was added last. The reaction was stirred for 3 hours then diluted with water and extracted into methylene chloride. The combined organic layers was dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography with 1.5% methanol-methylene chloride (gravity column) as eluant the title compound (195 mg) was obtained.
Step 3
Methanesulfonic acid 3-{4-[6-methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophene-3-car bonyl]-phenyl}-prop-2-ynyl ester. The product from Step 2 (195 mg, 0.46 mmol) was dissolved in 3 mL of methylene chloride and treated with 127 mL of triethylamine and methanesulfonyl chloride (53 mL,
0.68 mmol) and stirred 30 minutes at room temperature. The reaction was concentrated and extracted into ethyl acetate. The combined organic layers was washed with brine and dried over anhydrous magnesium sulfate. After filtration, concentration the title compound (205 mg) was obtained.
Step 4
[6-Methoxy-2-(4-methoxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin-1-yl-prop-1-ynyl)-phenyl]-methanone. The product from Step 3 (205 mg, 0.4 mmol) was combined with cesium carbonate (197 mg, 0.6 mmol), piperidine (44 mL, 0.44 mmol) in dimethylformamide at room temperature. After four hours the reaction was diluted with ethyl acetate and washed with water and brine. The organic layer was dried over anhydrous magnesium sulfate. After filtration, concentration the title compound (120 mg) was obtained.
Step 5
[6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin-1-yl-prop-1-ynyl)-phenyl]-methanone. The product from Step 4 (120 mg, 0.24 mmol) was dissolved in methylene chloride (0.5 mL), cooled to 0°C and treated with boron tribromide (1.2 mL, 1 M, 1.2 mmol) and stirred for 30 minutes. The reaction was quenched with saturated sodium bicarbonate solution and extracted intochloroform. The combined organic layers was dried over anhydrous magnesium sulfate. After filtration, concentration and silica gel column chromatography with 2% methanol- methylene chloride as eluant the title compound (24 mg) was obtained.
1H-NMR (MeOH-d4) d 7.6 (d, 2H), 7.5 (d, 1 H), 7.28 (d, 2H), 7.25 (d, 1 H), 7.1 (d, 2H), 6.88 (dd, 1 H), 6.58 (d, 2H), 3.45 (s, 2H), 2.57 (m, 4H), 1.62 (m, 4H), 1.5 (m, 2H)
Figure imgf000075_0001
Figure imgf000076_0001
Figure imgf000077_0001
Figure imgf000078_0001
Figure imgf000079_0001

Claims

A compound of the formula
Figure imgf000080_0001
wherein
A, B and Z are independently
(a) -CH=,
(b) -CR4=,
(c) =N-;
X is
(a) -S-,
(b) -O-,
(c) -NH-,
(d) -NR2-,
(e) -CH2CH2-,
(f) -CH2CH2CH2-,
(g) -CH2O-,
(h) -OCH2-,
(i) -CH2S-,
Figure imgf000080_0002
(k) -SCH2-,
(I) -N=CR2-,
(m) -R2C=N-;
Y is
(a) phenyl, optionally substituted with 1-3 substituents independently selected from the group consisting of halo, hydroxy, C1-C4 alkyl, C1-C4 alkoxy
Figure imgf000081_0001
and R1SO2NH-;
(b) C1-C8 alkyl, said alkyl groups being optionally substituted with 1-3 substituents independently selected from the group consisting of
-OH, -OR2,
Figure imgf000081_0002
, and R1SO2NH-;
(c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from the group consisting of -OH, -OR1,-NH2,
Figure imgf000081_0003
, and R1SO2NH-;
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from the group consisting of -OH,
-OR1,
Figure imgf000081_0004
and R1SO2NH-;
(e) a five membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2-, -N=, and -S(O)n-, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-
CO2H, -CN, -CONHR1, -SO2NHR1,-NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1,-NHCOR1, -NO2, and -aryl;
(f) a six membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms independently selected from the group consisting of -O-, -NR2-, -N=, and -S(O)n- optionally substituted with 1 -3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C1-C4 alkyl,
trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H,-CN, -CONHR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1, -NHCOR1, -NO2, and -aryl; or
(g) a bicyclic ring system consisting of a five or six membered saturated, unsaturated or partially unsaturated heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms independently selected from the group consisting of -O-, -NR2-, -N=, and -S(O)n-, optionally substituted with 1-3
substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy,
trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H, -CN, - CONHR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, - NHSO2R1, -NHCOR1, -NO2, -OH, and -aryl;
D is
(a) -CO-,
(b) -CR2R3-,
(c) -CONH-,
(d) -NHCO-,
(e) -CR2 (OH)-,
(f) -CONR2-,
(g) -NR2CO-,
Figure imgf000082_0001
Figure imgf000082_0002
Figure imgf000082_0003
E is
(a) a single bond;
(b) phenyl, or phenyl substituted with up to three substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1- C4)alkyl, aryl (C1-C4)alkyl,-CO2H,- CN,-CONHR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1,-NHCOR1, -NO2, and -aryl; or
(c) a 5 or 6 membered saturated, unsaturated or partially unsaturated heterocycle, optionally fused to a phenyl ring, containing up to two heteroatoms independently selected from the group consisting of -O-, -NR2-,-N=, and -S(O)n- optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C1- C4)alkyl, aryl (C1-C4)alkyl,-CO2H,-CN, -CONHR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4 dialkylamino, -NHSO2R1, -NHCOR1, -NO2, and -aryl; Z1 is
(a) -(CH2)p W(CH2)q-,
(b) -O(CH2)p CR5 R6-,
(c) -O(CH2)pW(CH2)q-;
G is
(a) -NR7 R8,
(b)
Figure imgf000083_0001
wherein n is 0, 1 or 2; m is 1 , 2 or 3; Z2 is -NH-, -O-,-S(O)n-, -CH2- or
-CO-; optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally and independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from
(1) -OR1,
(2) -SO2NR2R3, (3) ,
Figure imgf000084_0001
(4) ,
Figure imgf000084_0002
(5) halogen,
(6) ,
Figure imgf000084_0003
(7) ,
Figure imgf000084_0004
(8)
,
Figure imgf000084_0005
(9)
,
Figure imgf000084_0006
(10) ,
Figure imgf000085_0001
(11) ,
Figure imgf000085_0002
(12) ,
Figure imgf000085_0003
(13) -C≡CR1,
Figure imgf000085_0004
Figure imgf000085_0005
,
Figure imgf000085_0006
(17) ,
Figure imgf000085_0007
(18) Ar-CH2-,
Figure imgf000085_0008
Figure imgf000085_0009
(21)-(CF2)mCF3, (22)
,
Figure imgf000086_0001
(C) ,
Figure imgf000086_0002
(d) ,
Figure imgf000086_0003
(e) a 5 or 6 membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2-,-N=, and -S(O)n- optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy (C^C^alkyl, aryl (C1-C4)alkyl,-CO2H, -CN, - CONHR1, -SO2NHR1, -NH2, C1-C4alkylamino, C1-C4dialkylamino, - NHSO2R1, -NHCOR1, -NO2, and -aryl; said heterocycle being joined to group Z1 by a carbon to carbon bond or a carbon-nitrogen bond; (f) a bicyclic amine containing a five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, halo, C1-C4 alkyl, trihalomethyl, C1-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C1-C4 alkylthio, C1-C4 alkylsulfinyl, C1-C4 alkylsulfonyl, hydroxy
(C1-C4)alkyl, aryl (C1-C4)alkyl,-CO2H,-CN,-CONHR1, -SO2NHR1, -NH2, C1-C4 alkylamino, C1-C4dialkylamino, -NHSO2R1, -NHCOR1, -NO2, and - aryl;
Ar is phenyl or naphthyl optionally substituted with up to three substituents independently selected form R4;
W is
(a) -CH2-,
(b) -CH=CH-,
(c) -O-,
(d) -NR2-,
(e) -S(O)n-,
Figure imgf000087_0002
,
(g) -CR2(OH)-,
(h) -CONR2-,
(i) -NR2CO-,
(j) ,
Figure imgf000087_0001
(k) -C≡C-;
R is
(a) halogen,
(b) -NR3R2,
(c) -NHCOR2,
(d) -NHSO2R2,
(e) -CR2R3OH,
(f) -CONR2R3, (g) -SO2NR2R3,
(h) hydroxyl,
(i) R1O-,
Figure imgf000088_0001
R1 is C1-C6 alkyl or phenyl optionally substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
R2 and R3 are independently
(a) hydrogen,
(b) C1-C4 alkyl;
R4 is
(a) hydrogen,
(b) halogen,
(c) C1-C4 alkyl,
(d) C1-C4 alkoxy,
(e) C1-C4 acyloxy,
(f) C1-C4 alkylthio,
(g) C1-C4 alkylsulfinyl,
(h) C1-C4 alkylsulfonyl,
(i) hydroxy (C1-C4)alkyl,
(j) aryl (C1-C4)alkyl,
(k) -CO2H,
(I) -CN,
(m) -CONHOR,
(n) -SO2NHR,
(o) -NH2,
(p) C1-C4 alkylamino,
(q) C1-C4 dialkylamino,
(r) -NHSO2R,
(s) -NO2,
(t) -aryl;
R5 and R6 are independently C1-C8 alkyl or together form a C3-C10 carbocyclic ring; R7 and R8 are independently
(a) phenyl,
(b) a C3-C10 carbocyclic ring, saturated or unsaturated,
(c) a C3-C10 heterocyclic ring containing up to two heteroatoms selected from -O-, -N- and -S-,
(d) H,
(e) C1-C6 alkyl,
(f) or form a 3 to 8 membered nitrogen containging ring with R5 or R6; R7 and R8 in either linear or ring form may optionally be substituted with up to three substituents independently selected from C1-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R7 and R8 may be optionally fused to a phenyl ring;
m is 1 , 2 or 3;
n is 0, 1 or 2;
p is 0, 1 , 2 or 3;
q is 0, 1 , 2, or 3;
and geometric and optical isomers, pharmaceutically acceptable esters, ethers and salts thereof;
with the proviso that when A, B and Z are each -CH=, Y is 4-hydroxy phenyl, X is sulfur, D is -CO-, E is 1 ,4-disubstituted phenyl, R is -OH, and Z1 is -OCH2 CH2- then G must be a group other than , ,
Figure imgf000089_0001
Figure imgf000089_0002
Figure imgf000089_0003
or -N-(C1-C4 alkyl)2; and with the further proviso that if R is
Figure imgf000089_0004
, G must be a group other than ;
Figure imgf000089_0005
and with the further proviso that when A, B and Z are each -CH = , X is S, Y is cycloalkyl or cycloalkenyl, D is -CO-, E is 1 ,4 disubstituted phenyl, and Z1 is methylene, -O(CH2)m-, ethylene or propylene; G must be other than , or
Figure imgf000090_0001
Figure imgf000090_0002
Figure imgf000090_0003
and with the further proviso that when D is -CR2R3- and W is -CO- or -S(O)n-; G must be other than:
a) -NR11R12 where R11 and R12 are separately hydrogen, alkyl, alkenyl, cycloalkyl, haloalkyl, aryl or arylalkyl;
b)
where n is 0, 1 or 2; m is 1 , 2 or 3; and Z2 is -NH-, -O-
Figure imgf000090_0004
-S- or -CH2-;
and with the further proviso that when A, B and Z are each -CH=, Y is 4- hydroxyphenyl, X is -CH2-CH2- or -CH=CH-; D is CO, E is 1 , 4-disubstituted phenyl, and Z1 is -OCH2CH2-; then G must be a group other than
Figure imgf000090_0005
or
Figure imgf000090_0006
.
2. A compound of claim 1 wherein R is -OH.
3. A compound of claim 1 wherein A B and Z are independently selected from - CH= and -CF=.
4. A compound of claim 1 wherein X is -S-.
5. A compound of claim 1 wherein D is -CO- or -CH2-.
6. A compound of claim 1 wherein E is 1 ,4-linked phenyl or pyridyl, pyrimidine,
Figure imgf000090_0007
or .
Figure imgf000090_0008
Figure imgf000090_0009
7. A compound of claim 1 wherein Z1 is -OCH2CH2-, -CH2CH2-, -CH2-
-C≡C-CH2-, or Z in combination with G is
Figure imgf000091_0007
.
Figure imgf000091_0008
8. A compound of claim 1 wherein G is
Figure imgf000091_0006
9. A compound of claim 1 wherein R is -OH; A, B and Z are -CH=; X is S; Y is
Figure imgf000091_0004
or
Figure imgf000091_0005
;
D is
Figure imgf000091_0003
or -CH2- ,
E is
Figure imgf000091_0001
or
Figure imgf000091_0002
; Z1 is -CH2-CH2-CH2- or
Figure imgf000092_0001
10. A compound of claim 1 wherein:
A, B and Z are -CH=;
X is -S-;
Y is phenyl, 4-hydroxyphenyl, 4-chlorophenyl, 4-fluorophenyl,
Figure imgf000092_0003
Figure imgf000092_0002
or ;
R is -OH-;
D is -CO- or -CH2-;
E is phenyl or pyridyl; and
Z1 is -OCH2CH2-, -C≡C-CH2-, -OCH2-, or -NHCH2CH2-
1 1. A compound of claim 10 wherein G is: wherein n is 0, 1 or 2;
Figure imgf000092_0004
m is 1 , 2 or 3 and Z2 is -NH-, -O-, -S- or -CH2-
12. A compound of claim 10 wherein G is:
Figure imgf000092_0005
13. A compound of claim 10 wherein G is
Figure imgf000093_0001
,
Figure imgf000093_0003
, or
Figure imgf000093_0004
.
Figure imgf000093_0002
14. A compound of claim 1 wherein Z is =N- or -CF=; X is -S-; Y is 4- hydroxyphenyl; R is -OH-; D is -CO- or CH2-; E is phenyl or pyridyl; and Z1 is -OCH2CH2-.
15. A compound of claim 1 which is {4-[2-(2-Aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone.
16. A compound of claim 1 which is [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(1-methyl-piperidin-2-yl-methoxy)-phenyl]-methanone.
17. A compound of claim 1 which is [2-(4-Fluoro-phenyl)-6-hydroxy-benzo[b]thiophen-3-yl]-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-methanone.
18. A compound of claim 1 which is [6-Hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-[4-(3-piperidin-1-yI-prop-1-ynyl)-phenyl]-methanone.
19. A compound of claim 1 which is 2-(4-Hydroxy-phenyl)-3-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-benzo[b]thiophen-6-ol.
20. A method of treating bone loss associated with estrogen deficiency in a mammal which comprises administering to a mammal in need of such treatment an amount of a compound of claim 1 which is effective in treating said bone loss.
21. A method for the treatment or prevention of cardiovascular disease which comprises administering to a mammal in need of such treatment an amount of a compound of claim 1 which is effective in treating or preventing said cardiovascular disease. .
22. A method for the treatment or prevention of diseases or syndromes which are caused by an estrogen deficient state in a mammal which comprises administering to a mammal in need of such treatment or prevention an amount of a compound of claim 1 which is effective in treating said disease or syndrome.
PCT/IB1994/000282 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists WO1995010513A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US08/628,605 US6756388B1 (en) 1993-10-12 1994-09-13 Benzothiophenes and related compounds as estrogen agonists
NZ271733A NZ271733A (en) 1993-10-12 1994-09-19 3,6-disubsituted benzothiophene derivatives
PL94313905A PL313905A1 (en) 1993-10-12 1994-09-19 Benzothiophenes and homologous compounds acting as oestrogen antagonists
AU75453/94A AU7545394A (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists
EP94925597A EP0723537A1 (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists
BR9407790A BR9407790A (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists
JP7511552A JPH08511273A (en) 1993-10-12 1994-09-19 Benzothiophene and related compounds as estrogen agonists
KR1019960701899A KR960704874A (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists (BENZOTHIOPHENES AND RELATED COMPOUNDS AS ESTROGEN AGONISTS)
NO961432A NO961432D0 (en) 1993-10-12 1996-04-11 Benzophiophenes and related compounds as estrogen agonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13538693A 1993-10-12 1993-10-12
US08/135,386 1993-10-12

Publications (1)

Publication Number Publication Date
WO1995010513A1 true WO1995010513A1 (en) 1995-04-20

Family

ID=22467873

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1994/000282 WO1995010513A1 (en) 1993-10-12 1994-09-19 Benzothiophenes and related compounds as estrogen agonists

Country Status (19)

Country Link
US (1) US6756388B1 (en)
EP (1) EP0723537A1 (en)
JP (1) JPH08511273A (en)
KR (1) KR960704874A (en)
CN (1) CN1133040A (en)
AU (1) AU7545394A (en)
BR (1) BR9407790A (en)
CA (1) CA2173243A1 (en)
CO (1) CO4290353A1 (en)
CZ (1) CZ105696A3 (en)
FI (1) FI944771A (en)
HU (1) HUT75231A (en)
IL (1) IL111187A0 (en)
NO (1) NO961432D0 (en)
NZ (1) NZ271733A (en)
PE (1) PE22095A1 (en)
PL (1) PL313905A1 (en)
WO (1) WO1995010513A1 (en)
ZA (1) ZA947911B (en)

Cited By (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0703231A1 (en) * 1994-09-20 1996-03-27 Eli Lilly And Company 2-(4-Hydroxyphenyl)benzothiophene compounds, compositions and methods for alleviating the symptoms of post-menopause syndrome
WO1996009045A1 (en) * 1994-09-19 1996-03-28 Eli Lilly And Company Antiestrogenic benzothiophenyl compounds
WO1996009040A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Benzofuran compounds, compositions, and methods
WO1996009039A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
EP0716855A2 (en) * 1994-12-14 1996-06-19 Pfizer Inc. Use of estrogen agonists for treating prostatic disease, obesity and bone loss
EP0731093A1 (en) * 1995-03-10 1996-09-11 Eli Lilly And Company Naphthyl pharmaceutical compounds
US5567828A (en) * 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
EP0738725A2 (en) * 1995-04-21 1996-10-23 Eli Lilly And Company Benzothiophenes with novel basic side chains
EP0747376A1 (en) * 1995-06-07 1996-12-11 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
WO1997001549A1 (en) * 1995-06-26 1997-01-16 Eli Lilly And Company Benzothiophene compounds
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
EP0759434A1 (en) * 1995-08-17 1997-02-26 Eli Lilly And Company Benzothiophene compounds
EP0761659A1 (en) * 1995-07-31 1997-03-12 Eli Lilly And Company Naphthyl and dihydronaphthyl compounds as medicaments
US5622974A (en) * 1995-03-10 1997-04-22 Eli Lilly And Company α-substituted-3-benzyl-benzofurans
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
EP0791590A1 (en) * 1996-02-21 1997-08-27 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
EP0791591A1 (en) * 1996-02-22 1997-08-27 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
WO1997041851A1 (en) * 1996-05-09 1997-11-13 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US5705507A (en) * 1995-03-10 1998-01-06 Eli Lilly And Company Aplha-substituted-3-benzyl-benzofurans
EP0819686A1 (en) * 1996-07-15 1998-01-21 Eli Lilly And Company Benzothiophene compounds, and uses and formulations thereof
US5723474A (en) * 1995-02-28 1998-03-03 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
EP0826682A1 (en) * 1996-08-28 1998-03-04 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation, and methods of use
WO1998008797A1 (en) * 1996-08-29 1998-03-05 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods of use
EP0831089A1 (en) * 1996-09-24 1998-03-25 Eli Lilly And Company Benzothiophene compounds, intermediates, processes, compositions, and methods
EP0832888A1 (en) * 1996-09-27 1998-04-01 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
EP0832891A1 (en) * 1996-09-26 1998-04-01 Eli Lilly And Company Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods
EP0835872A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
EP0835871A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
EP0838464A1 (en) * 1996-10-25 1998-04-29 Eli Lilly And Company Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
EP0843999A1 (en) * 1996-11-15 1998-05-27 Pfizer Inc. Use of estrogen agonists/antagonists for the manufacture of a medicament in the treatment of atherosclerosis independent of a lipid lowering effect
US5760030A (en) * 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
US5792762A (en) * 1996-09-26 1998-08-11 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions and methods
US5821253A (en) * 1996-09-26 1998-10-13 Eli Lilly And Company Tetrahydrobenzo a!fluorene compounds and methods of use
EP0875510A1 (en) * 1997-04-30 1998-11-04 Eli Lilly And Company Process for preparing benzothiophenes
WO1998048787A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES
WO1998048792A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES
WO1998048793A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
US5843934A (en) * 1993-11-05 1998-12-01 University Of Florida Research Foundation, Inc. Uses of estrogen compounds for the treatment of disease
US5843965A (en) * 1996-08-29 1998-12-01 Eli Lilly And Company Benzo B! thiophene compounds, intermediates, processes, compositions, and methods
US5843940A (en) * 1996-10-24 1998-12-01 Eli Lilly And Company Benzothiophene compounds, compositions, and method
WO1998056812A2 (en) * 1997-06-10 1998-12-17 Karo Bio Ab Estrogen receptor crystals and ligands
US5852193A (en) * 1997-04-30 1998-12-22 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
US5856341A (en) * 1996-09-26 1999-01-05 Eli Lilly And Company Benzo B! indeno 2,1-D! thiophene compounds, intermediates, processes, compositions and methods
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
EP0895989A1 (en) * 1997-08-07 1999-02-10 Eli Lilly And Company 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity
EP0902025A2 (en) * 1997-08-11 1999-03-17 Eli Lilly And Company Benzothiophenes for treatment of estrogen related conditions
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US5889000A (en) * 1996-09-26 1999-03-30 Eli Lilly And Company Naphthofluorene compounds, intermediates, compositions and methods
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5922753A (en) * 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5939444A (en) * 1996-10-23 1999-08-17 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US5952350A (en) * 1996-10-24 1999-09-14 Eli Lilly And Company Naphthyl compounds and compositions, as estrogen receptor binding agents
US5958917A (en) * 1996-09-26 1999-09-28 Eli Lilly And Company Benzofluorene compounds, intermediates, compositions, and methods
US5958969A (en) * 1996-10-10 1999-09-28 Eli Lilly And Company Benzo b!thiophene compounds, intermediates, formulations, and methods
US5958916A (en) * 1996-08-29 1999-09-28 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US5965573A (en) * 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5977383A (en) * 1996-09-25 1999-11-02 Eli Lilly And Company Process for the synthesis of benzothiophenes
US5977093A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5985897A (en) * 1996-10-24 1999-11-16 Muehl; Brian Stephen Benzothiphene compounds, intermediates, compositions, and methods
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5994547A (en) * 1997-04-30 1999-11-30 Eli Lilly And Company Process for preparing benzo[b]thiophenes
US5994370A (en) * 1997-04-25 1999-11-30 Eli Lilly And Company Indene compounds having activity as SERMS
US5998442A (en) * 1996-08-29 1999-12-07 Eli Lilly And Company Benzo [B] thiophene compounds, and compositions for treating bone loss, and hyperlipidemia
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6008377A (en) * 1996-03-19 1999-12-28 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxy-benzo[B]thiophenes
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
US6025382A (en) * 1995-10-31 2000-02-15 Eli Lilly And Company Antithrombotic diamines
WO2000023424A1 (en) * 1998-10-20 2000-04-27 Isis Innovation Limited Epibatidine analogues as acetylcholine receptor antagonists
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
US6077852A (en) * 1997-04-09 2000-06-20 Eli Lilly And Company Treatment of central nervous system disorders with selective estrogen receptor modulators
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
US6133262A (en) * 1998-10-28 2000-10-17 Eli Lilly And Company Antithrombotic agents
US6140341A (en) * 1996-03-13 2000-10-31 Hoechst Aktiengesellschaft Aminoalkyl and acylaminoalkyl ethers, process for their preparation, and their use as bradykinin receptor antagonists
US6147088A (en) * 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6153622A (en) * 1995-01-09 2000-11-28 Pfizer, Inc. Estrogen agonists/antagonists
US6197975B1 (en) * 1995-12-14 2001-03-06 Merck & Co. , Inc. Antagonists of gonadotropin releasing hormone
US6245761B1 (en) 1995-09-01 2001-06-12 Eli Lilly And Company Indolyl neuropeptide Y receptor antagonists
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
US6288105B1 (en) 1997-04-30 2001-09-11 Eli Lilly And Company Antithrombotic agents
US6316464B1 (en) 1997-10-20 2001-11-13 Syntex (U.S.A.) Llc P38 MAP kinase inhibitors
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6350884B1 (en) 1996-06-25 2002-02-26 Eli Lilly And Company Acrylic and propionic acid compounds, intermediates, processes, compositions, and method
US6350774B1 (en) 1997-04-30 2002-02-26 Eli Lilly And Company Antithrombotic agents
WO2002016340A1 (en) * 2000-08-23 2002-02-28 Sanofi-Synthelabo Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
WO2002016339A1 (en) * 2000-08-23 2002-02-28 Sanofi-Synthelabo Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
US6355632B1 (en) 1995-02-28 2002-03-12 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US6384053B1 (en) 1995-03-10 2002-05-07 Eli Lilly And Company α-substituted-1-benzyl-napthyls
US6391901B1 (en) 1997-04-30 2002-05-21 Eli Lilly And Company Thrombin inhibitors
US6395755B1 (en) * 1995-03-10 2002-05-28 Eli Lilly And Company Benzothiophene pharmaceutical compounds
US6403614B1 (en) 1997-10-03 2002-06-11 Eli Lilly And Company Benzothiophenes
US6414154B1 (en) 1998-05-20 2002-07-02 Smithkline Beecham P.L.C. Tetraisoquinoline derivatives as modulators of dopamine D3 receptors
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
US6432983B1 (en) 1996-07-02 2002-08-13 Eli Lilly And Company Benzothiophene compounds intermediates processes and methods of use
US6451817B1 (en) 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
EP1283209A1 (en) * 2000-05-18 2003-02-12 Daiichi Pharmaceutical Co., Ltd. Novel benzothiophene derivatives
US6599925B2 (en) 2001-06-20 2003-07-29 Wyeth Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US6599920B2 (en) 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
US6608090B1 (en) 1995-04-21 2003-08-19 Eli Lilly And Company Benzothiophenes with novel basic side chains
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
US6653328B1 (en) 1995-03-10 2003-11-25 Eli Lilly And Company 3-benzyl-benzothiophenes
WO2004000314A1 (en) * 2002-06-21 2003-12-31 Qlt Inc. Methods of using benzothiophenone derivatives to treat cancer or inflammation
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
US6770643B2 (en) 1999-12-24 2004-08-03 Aventis Pharma Limited Azaindoles
US6800654B2 (en) 2001-06-20 2004-10-05 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
WO2005000834A1 (en) * 2003-06-10 2005-01-06 Eli Lilly And Company Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US6897207B2 (en) 2001-06-21 2005-05-24 Aventis Pharmaceuticals Inc. Azaindoles
US6911456B2 (en) 1996-02-28 2005-06-28 Pfizer Inc Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2005073206A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US7056931B2 (en) 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7105542B2 (en) * 2002-08-02 2006-09-12 The Ohio State University Research Foundation 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
GR20050100282A (en) * 2005-06-08 2007-01-19 Αλεξης Μιχαηλ Tissue-specific antiestrogens specific for estrogen receptor
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7323483B2 (en) 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US7399867B2 (en) 2002-07-22 2008-07-15 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7446121B2 (en) 2004-11-23 2008-11-04 Pfizer Inc. Pyrazole-based HMG CoA reductase inhibitors
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7605172B2 (en) 2004-08-23 2009-10-20 Wyeth Thiazolo-naphthyl acids
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
WO2010040274A1 (en) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 Novel dopamine d3 receptor ligands, the preparation and use thereof
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US8497294B2 (en) 2007-03-14 2013-07-30 Astex Therapeutics Limited Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
WO2013130832A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US8877801B2 (en) 2013-02-19 2014-11-04 Novartis Ag Compounds and compositions as selective estrogen receptor degraders
EP2826475A1 (en) 2007-10-16 2015-01-21 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
US10160752B2 (en) * 2012-10-24 2018-12-25 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US10888545B2 (en) 2012-10-24 2021-01-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US20210260052A1 (en) * 2018-07-12 2021-08-26 Eli Lilly And Company Selective estrogen receptor degraders
US11439649B2 (en) 2018-02-21 2022-09-13 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3171099A (en) * 1998-04-17 1999-11-08 Senga Pharmaceutical Laboratory Inc. 1-heteroindene derivatives and medicinal composition containing the same
FR2813307B1 (en) * 2000-08-23 2002-11-08 Sanofi Synthelabo AMINOALKENYLBENZOYL-BENZOFURANS OR BENZOTHIOPHENES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM
EP1416028A1 (en) * 2002-10-30 2004-05-06 Covion Organic Semiconductors GmbH New method for the production of monomers useful in the manufacture of semiconductive polymers
CA2574310A1 (en) * 2004-07-22 2006-02-02 Wyeth Method for treating nervous system disorders and conditions
EP1773321A2 (en) * 2004-07-22 2007-04-18 Wyeth Method for treating nervous system disorders and conditions
CN101014337A (en) * 2004-07-22 2007-08-08 惠氏公司 Method for treating nervous system disorders and conditions
JP4761112B2 (en) * 2005-02-16 2011-08-31 公益財団法人新産業創造研究機構 A composition for preventing or treating bone metabolic diseases, comprising a benzofuran derivative
US20070021488A1 (en) * 2005-07-21 2007-01-25 Wyeth Method for treating nervous system disorders and conditions
KR101123178B1 (en) * 2009-04-09 2012-06-13 (주)에스메디 2-aryl benzothiophene derivatives or pharmaceutically acceptable salts thereof, preparation method thereof, and phrmaceutical composition for the diagnosis or treatment of degenerative brain disease containing the same as an active ingredient
CA2769038A1 (en) 2009-07-31 2011-02-03 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Antiangiogenic small molecules and methods of use
WO2011029088A2 (en) * 2009-09-07 2011-03-10 Dr. Reddy's Laboratories Ltd. Preparation of raloxifene and its salts
EP2314581B1 (en) * 2009-10-23 2012-07-25 Hexal AG A process for preparing benzo[b]thiophene derivatives

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0471609A1 (en) * 1990-08-06 1992-02-19 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
EP0516257A1 (en) * 1991-05-25 1992-12-02 Schering Aktiengesellschaft Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same
WO1993010113A1 (en) * 1991-11-15 1993-05-27 Teikoku Hormone Mfg. Co., Ltd. Novel benzothiophene derivative

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4133814A (en) * 1975-10-28 1979-01-09 Eli Lilly And Company 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
EP0062503A1 (en) * 1981-04-03 1982-10-13 Eli Lilly And Company Benzothiophene compounds and process for preparing them
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
EP0471609A1 (en) * 1990-08-06 1992-02-19 Sanofi Benzofuran Derivatives, Benzothiophenes, Indoles or Indolizines, Process for Production and Compositions containing them
EP0516257A1 (en) * 1991-05-25 1992-12-02 Schering Aktiengesellschaft Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same
WO1993010113A1 (en) * 1991-11-15 1993-05-27 Teikoku Hormone Mfg. Co., Ltd. Novel benzothiophene derivative

Cited By (262)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319914B1 (en) 1993-11-05 2001-11-20 Apollo Biopharmaceuticals, Inc. Cytoprotective effect of polycyclic phenolic compounds
US5843934A (en) * 1993-11-05 1998-12-01 University Of Florida Research Foundation, Inc. Uses of estrogen compounds for the treatment of disease
US5596106A (en) * 1994-07-15 1997-01-21 Eli Lilly And Company Cannabinoid receptor antagonists
US5747524A (en) * 1994-07-15 1998-05-05 Eli Lilly And Company Cannabinoid receptor antagonists
WO1996009045A1 (en) * 1994-09-19 1996-03-28 Eli Lilly And Company Antiestrogenic benzothiophenyl compounds
US6399778B1 (en) 1994-09-19 2002-06-04 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
AT407988B (en) * 1994-09-19 2001-07-25 Lilly Co Eli NEW PHARMACEUTICAL PRODUCT
US5629425A (en) * 1994-09-19 1997-05-13 Eli Lilly And Company Haloalkyl hemisolvates of 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-piperidinoethoxy)-benzoyl]benzo[b]thiophene
US6472531B1 (en) 1994-09-19 2002-10-29 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxybenzo[b]thiophenes
US5731327A (en) * 1994-09-19 1998-03-24 Eli Lilly And Company Synthesis of 3- 4-(2-aminoethoxy)benzoyl!-2-aryl-6-hydroxybenzo b!thiophenes
WO1996009040A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Benzofuran compounds, compositions, and methods
EP0703231A1 (en) * 1994-09-20 1996-03-27 Eli Lilly And Company 2-(4-Hydroxyphenyl)benzothiophene compounds, compositions and methods for alleviating the symptoms of post-menopause syndrome
WO1996009039A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Naphthyl compounds, intermediates, processes, compositions, and methods
WO1996009041A1 (en) * 1994-09-20 1996-03-28 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US6407243B1 (en) * 1994-09-20 2002-06-18 Eli Lilly And Company Benzofuran compounds, compositions, and methods
EP0716855A2 (en) * 1994-12-14 1996-06-19 Pfizer Inc. Use of estrogen agonists for treating prostatic disease, obesity and bone loss
US5589482A (en) * 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
EP0716855A3 (en) * 1994-12-14 1996-07-10 Pfizer
US6204286B1 (en) * 1995-01-09 2001-03-20 Pfizer Inc Estrogen agonists/antagonists
USRE39558E1 (en) 1995-01-09 2007-04-10 Pfizer Inc. 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis
US6441193B1 (en) 1995-01-09 2002-08-27 Pfizer Inc. Estrogen agonists/antagonists
US6153622A (en) * 1995-01-09 2000-11-28 Pfizer, Inc. Estrogen agonists/antagonists
US5723474A (en) * 1995-02-28 1998-03-03 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5998441A (en) * 1995-02-28 1999-12-07 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5856339A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5919800A (en) * 1995-02-28 1999-07-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5969142A (en) * 1995-02-28 1999-10-19 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions and methods
US6355632B1 (en) 1995-02-28 2002-03-12 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods
US5856340A (en) * 1995-02-28 1999-01-05 Eli Lilly And Company Method of treating estrogen dependent cancers
US5977093A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6030986A (en) * 1995-02-28 2000-02-29 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6197790B1 (en) 1995-02-28 2001-03-06 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5981765A (en) * 1995-02-28 1999-11-09 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5985898A (en) * 1995-02-28 1999-11-16 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US5986109A (en) * 1995-02-28 1999-11-16 Eli Lilly And Company Benzothiophene compounds, intermediates, compositions, and methods
US6395755B1 (en) * 1995-03-10 2002-05-28 Eli Lilly And Company Benzothiophene pharmaceutical compounds
US5622974A (en) * 1995-03-10 1997-04-22 Eli Lilly And Company α-substituted-3-benzyl-benzofurans
EP0731093A1 (en) * 1995-03-10 1996-09-11 Eli Lilly And Company Naphthyl pharmaceutical compounds
US6451817B1 (en) 1995-03-10 2002-09-17 Eli Lilly And Company Alpha-substituted-1-benzyl-napthyls
US6417199B1 (en) 1995-03-10 2002-07-09 Eli Lilly And Company 3-benzyl-benzothiophenes
US6384053B1 (en) 1995-03-10 2002-05-07 Eli Lilly And Company α-substituted-1-benzyl-napthyls
US6653328B1 (en) 1995-03-10 2003-11-25 Eli Lilly And Company 3-benzyl-benzothiophenes
US5705507A (en) * 1995-03-10 1998-01-06 Eli Lilly And Company Aplha-substituted-3-benzyl-benzofurans
US5863936A (en) * 1995-04-18 1999-01-26 Geron Corporation Telomerase inhibitors
US6608090B1 (en) 1995-04-21 2003-08-19 Eli Lilly And Company Benzothiophenes with novel basic side chains
WO1996032937A1 (en) * 1995-04-21 1996-10-24 Eli Lilly And Company Benzothiophenes with novel basic side chains
EP0738725A2 (en) * 1995-04-21 1996-10-23 Eli Lilly And Company Benzothiophenes with novel basic side chains
EP0738725A3 (en) * 1995-04-21 1997-03-05 Lilly Co Eli Benzothiophenes with novel basic side chains
US6444688B1 (en) 1995-06-07 2002-09-03 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
EP0747377A1 (en) * 1995-06-07 1996-12-11 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
EP0747376A1 (en) * 1995-06-07 1996-12-11 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US5567828A (en) * 1995-06-07 1996-10-22 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side
US5631247A (en) * 1995-06-07 1997-05-20 Eli Lilly And Company Compounds and compositions with nitrogen-containing non-basic side chains
US6440958B1 (en) 1995-06-26 2002-08-27 Eli Lilly And Company Acrylic and propionic acid compounds, intermediates, processes, compositions, and methods
WO1997001549A1 (en) * 1995-06-26 1997-01-16 Eli Lilly And Company Benzothiophene compounds
US5811421A (en) * 1995-07-31 1998-09-22 Eli Lilly And Company Naphthyl and dihydronaphthyl intermediates, compounds, compositions, and methods
EP0761659A1 (en) * 1995-07-31 1997-03-12 Eli Lilly And Company Naphthyl and dihydronaphthyl compounds as medicaments
US5728724A (en) * 1995-08-17 1998-03-17 Eli Lilly And Company Benzothiophene compounds
EP0759434A1 (en) * 1995-08-17 1997-02-26 Eli Lilly And Company Benzothiophene compounds
US6245761B1 (en) 1995-09-01 2001-06-12 Eli Lilly And Company Indolyl neuropeptide Y receptor antagonists
US6025382A (en) * 1995-10-31 2000-02-15 Eli Lilly And Company Antithrombotic diamines
US6265575B1 (en) 1995-10-31 2001-07-24 Eli Lilly And Company Antithrombotic diamines
US6251921B1 (en) 1995-10-31 2001-06-26 Eli Lilly And Company Antithrombotic diamines
US6197975B1 (en) * 1995-12-14 2001-03-06 Merck & Co. , Inc. Antagonists of gonadotropin releasing hormone
US6432982B1 (en) 1996-02-21 2002-08-13 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
EP0791590A1 (en) * 1996-02-21 1997-08-27 Eli Lilly And Company Benzothiophenes, and formulations and methods using same
EP0791591A1 (en) * 1996-02-22 1997-08-27 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6911456B2 (en) 1996-02-28 2005-06-28 Pfizer Inc Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions
EP0801066A1 (en) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterocyclic substituted benzothiophenes and pharmaceutical compositions
US6140341A (en) * 1996-03-13 2000-10-31 Hoechst Aktiengesellschaft Aminoalkyl and acylaminoalkyl ethers, process for their preparation, and their use as bradykinin receptor antagonists
US6008377A (en) * 1996-03-19 1999-12-28 Eli Lilly And Company Synthesis of 3-[4-(2-aminoethoxy)-benzoyl]-2-aryl-6-hydroxy-benzo[B]thiophenes
US5843984A (en) * 1996-05-09 1998-12-01 Eli Lilly And Company Sulfated benzothiophene derivatives, methods of use and formulations containing same
WO1997041851A1 (en) * 1996-05-09 1997-11-13 Eli Lilly And Company Benzothiophenes, formulations containing same, and methods
US6147088A (en) * 1996-05-20 2000-11-14 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
US6350884B1 (en) 1996-06-25 2002-02-26 Eli Lilly And Company Acrylic and propionic acid compounds, intermediates, processes, compositions, and method
US6432983B1 (en) 1996-07-02 2002-08-13 Eli Lilly And Company Benzothiophene compounds intermediates processes and methods of use
EP0819686A1 (en) * 1996-07-15 1998-01-21 Eli Lilly And Company Benzothiophene compounds, and uses and formulations thereof
US5792798A (en) * 1996-07-29 1998-08-11 Eli Lilly And Company Method for inhibiting plasminogen activator inhibitor 1
EP0826682A1 (en) * 1996-08-28 1998-03-04 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation, and methods of use
US6713494B1 (en) 1996-08-28 2004-03-30 Eli Lilly And Company Amorphous benzothiophenes, methods of preparation and methods of use
US6593345B1 (en) 1996-08-29 2003-07-15 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods of use
US5998442A (en) * 1996-08-29 1999-12-07 Eli Lilly And Company Benzo [B] thiophene compounds, and compositions for treating bone loss, and hyperlipidemia
US5958916A (en) * 1996-08-29 1999-09-28 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US5952513A (en) * 1996-08-29 1999-09-14 Eli Lilly And Company Benzo b! thiophene compounds
US6020513A (en) * 1996-08-29 2000-02-01 Eli Lilly And Company Dihydronaphthalene and naphthalene compounds, intermediates, formulations, and methods
US7105541B2 (en) 1996-08-29 2006-09-12 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods of use
WO1998008797A1 (en) * 1996-08-29 1998-03-05 Eli Lilly And Company Naphthyl compounds, intermediates, compositions, and methods of use
US5977382A (en) * 1996-08-29 1999-11-02 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, processes, compositions, and methods
US5977098A (en) * 1996-08-29 1999-11-02 Eli Lilly And Company Benzo[B]thiophene compounds, intermediates, processes, compositions, and methods
US5843965A (en) * 1996-08-29 1998-12-01 Eli Lilly And Company Benzo B! thiophene compounds, intermediates, processes, compositions, and methods
US6599920B2 (en) 1996-08-29 2003-07-29 Eli Lilly And Company Naphthalene compounds, intermediates, formulations, and methods
US6075151A (en) * 1996-09-24 2000-06-13 Eli Lilly And Company Benzothiophene compounds, intermediates, processes, compositions, and methods
EP0831089A1 (en) * 1996-09-24 1998-03-25 Eli Lilly And Company Benzothiophene compounds, intermediates, processes, compositions, and methods
US5843963A (en) * 1996-09-24 1998-12-01 Eli Lilly And Company Benzothiophene compounds, intermediates, processes, compositions, and methods
US5977383A (en) * 1996-09-25 1999-11-02 Eli Lilly And Company Process for the synthesis of benzothiophenes
US5792762A (en) * 1996-09-26 1998-08-11 Eli Lilly And Company Dihydrobenzofluorene compounds, intermediates, compositions and methods
US6133458A (en) * 1996-09-26 2000-10-17 Eli Lilly And Company Benzo[B]indeno[2, 1-D]thiophene compounds, intermediates, compositions, and methods
US5856341A (en) * 1996-09-26 1999-01-05 Eli Lilly And Company Benzo B! indeno 2,1-D! thiophene compounds, intermediates, processes, compositions and methods
US5959103A (en) * 1996-09-26 1999-09-28 Eli Lilly And Company Naphthofluorene compounds, intermediates, compositions, and methods
EP0832891A1 (en) * 1996-09-26 1998-04-01 Eli Lilly And Company Dihydrobenzo (B) indeno (2,1-D) thiophene compounds, intermediates, processes, compositions, and methods
US5958917A (en) * 1996-09-26 1999-09-28 Eli Lilly And Company Benzofluorene compounds, intermediates, compositions, and methods
US5889000A (en) * 1996-09-26 1999-03-30 Eli Lilly And Company Naphthofluorene compounds, intermediates, compositions and methods
US5821253A (en) * 1996-09-26 1998-10-13 Eli Lilly And Company Tetrahydrobenzo a!fluorene compounds and methods of use
US5981570A (en) * 1996-09-27 1999-11-09 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
EP0832888A1 (en) * 1996-09-27 1998-04-01 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US5948796A (en) * 1996-10-10 1999-09-07 Eli Lilly And Company Benzo B!thiophene compounds, intermediates, formulations, and methods
US5958969A (en) * 1996-10-10 1999-09-28 Eli Lilly And Company Benzo b!thiophene compounds, intermediates, formulations, and methods
EP0835871A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
EP0835872A1 (en) * 1996-10-10 1998-04-15 Eli Lilly And Company Benzo [b] thiophene compounds, intermediates, formulations, and methods
US5939444A (en) * 1996-10-23 1999-08-17 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6251901B1 (en) 1996-10-23 2001-06-26 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US6342514B1 (en) 1996-10-23 2002-01-29 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5990169A (en) * 1996-10-23 1999-11-23 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5919808A (en) * 1996-10-23 1999-07-06 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5922753A (en) * 1996-10-23 1999-07-13 Zymogenetics, Inc. Methods for treating bone deficit conditions with benzothiazole
WO1998017267A1 (en) * 1996-10-23 1998-04-30 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5948776A (en) * 1996-10-23 1999-09-07 Zymogenetic, Inc. Compositions and methods for treating bone deficit conditions
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5965573A (en) * 1996-10-23 1999-10-12 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5952350A (en) * 1996-10-24 1999-09-14 Eli Lilly And Company Naphthyl compounds and compositions, as estrogen receptor binding agents
US6121293A (en) * 1996-10-24 2000-09-19 Eli Lilly And Company Benzothiophene compounds, compositions, and methods
US5985897A (en) * 1996-10-24 1999-11-16 Muehl; Brian Stephen Benzothiphene compounds, intermediates, compositions, and methods
US5843940A (en) * 1996-10-24 1998-12-01 Eli Lilly And Company Benzothiophene compounds, compositions, and method
US5962475A (en) * 1996-10-25 1999-10-05 Eli Lilly And Company Substituted benzo(B)thiophene compounds having activity as selective estrogen receptor modulators
EP0838464A1 (en) * 1996-10-25 1998-04-29 Eli Lilly And Company Substituted benzo(b)thiophene compounds having activity as selective estrogen receptor modulators
US6124346A (en) * 1996-11-15 2000-09-26 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
EP0843999A1 (en) * 1996-11-15 1998-05-27 Pfizer Inc. Use of estrogen agonists/antagonists for the manufacture of a medicament in the treatment of atherosclerosis independent of a lipid lowering effect
US5886025A (en) * 1997-03-06 1999-03-23 Baylor University Anti-mitotic agents which inhibit tubulin polymerization
US6077852A (en) * 1997-04-09 2000-06-20 Eli Lilly And Company Treatment of central nervous system disorders with selective estrogen receptor modulators
US5994370A (en) * 1997-04-25 1999-11-30 Eli Lilly And Company Indene compounds having activity as SERMS
US6043360A (en) * 1997-04-30 2000-03-28 Eli Lilly And Company Intermediates and a process for preparing benzo[B]thiophenes
US5852193A (en) * 1997-04-30 1998-12-22 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
US6271227B1 (en) 1997-04-30 2001-08-07 Eli Lilly And Company Antithrombotic Agents
US6025495A (en) * 1997-04-30 2000-02-15 Eli Lilly And Company Regioselective alkylation process for preparing substituted benzo[b]thiophenes
US5994547A (en) * 1997-04-30 1999-11-30 Eli Lilly And Company Process for preparing benzo[b]thiophenes
US6288105B1 (en) 1997-04-30 2001-09-11 Eli Lilly And Company Antithrombotic agents
US6018056A (en) * 1997-04-30 2000-01-25 Eli Lilly And Company Intermediates and processes for preparing benzo (b) thiophenes
US6090949A (en) * 1997-04-30 2000-07-18 Eli Lilly And Company Processes for preparing benzothiophenes
US6075146A (en) * 1997-04-30 2000-06-13 Eli Lilly And Company Process for preparing benzoic acid derivative intermediates and benzothiophene pharmaceuticals
US6391901B1 (en) 1997-04-30 2002-05-21 Eli Lilly And Company Thrombin inhibitors
US6350774B1 (en) 1997-04-30 2002-02-26 Eli Lilly And Company Antithrombotic agents
EP0875510A1 (en) * 1997-04-30 1998-11-04 Eli Lilly And Company Process for preparing benzothiophenes
WO1998048787A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND A PROCESS FOR PREPARING BENZO[b]THIOPHENES
WO1998048792A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company A REGIOSELECTIVE ALKYLATION PROCESS FOR PREPARING SUBSTITUTED BENZO[b]THIOPHENES
WO1998048793A1 (en) * 1997-04-30 1998-11-05 Eli Lilly And Company INTERMEDIATES AND PROCESSES FOR PREPARING BENZO[b]THIOPHENES
US6274593B1 (en) 1997-05-01 2001-08-14 Smithkline Beecham P.L.C. Substituted tetrahydro isoquinolines as modulators of dopamine D3 receptors
WO1998056812A2 (en) * 1997-06-10 1998-12-17 Karo Bio Ab Estrogen receptor crystals and ligands
WO1998056812A3 (en) * 1997-06-10 1999-04-01 Karobio Ab Estrogen receptor crystals and ligands
US5760030A (en) * 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
EP0895989A1 (en) * 1997-08-07 1999-02-10 Eli Lilly And Company 1-[4-(Substituted alkoxy)benzyl] naphthalene compounds having estrogen inhibitory activity
US6509356B1 (en) 1997-08-07 2003-01-21 Eli Lilly And Company 1-(4-(Substituted alkoxy)benzyl)naphthalene compounds having estrogen inhibitory activity
US5908859A (en) * 1997-08-11 1999-06-01 Eli Lilly And Company Benzothiophenes for inhibiting hyperlipidemia
US6090843A (en) * 1997-08-11 2000-07-18 Eli Lilly And Company Benzothiophenes compounds which have useful pharmaceutical activity
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
EP0902025A3 (en) * 1997-08-11 1999-04-07 Eli Lilly And Company Benzothiophenes for treatment of estrogen related conditions
EP0902025A2 (en) * 1997-08-11 1999-03-17 Eli Lilly And Company Benzothiophenes for treatment of estrogen related conditions
US6017914A (en) * 1997-09-03 2000-01-25 Eli Lilly And Company Benzo[b]thiophene compounds, intermediates, formulations, and methods
US5929090A (en) * 1997-09-12 1999-07-27 Eli Lilly And Company 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
US5834488A (en) * 1997-09-19 1998-11-10 Eli Lilly And Company Dihydrobenzo B! indeno 2, 1-D! thiophene compounds, intermediates, processes, compositions and methods
US6403614B1 (en) 1997-10-03 2002-06-11 Eli Lilly And Company Benzothiophenes
US6316464B1 (en) 1997-10-20 2001-11-13 Syntex (U.S.A.) Llc P38 MAP kinase inhibitors
US6479507B2 (en) 1997-10-20 2002-11-12 Syntex (U.S.A.) Llc p38 MAP kinase inhibitors
US6649631B1 (en) 1997-10-23 2003-11-18 The Board Of Regents Of The University Of Texas System Compositions and methods for treating bone deficit conditions
US6284756B1 (en) 1998-04-30 2001-09-04 Eli Lilly And Company Antithrombotic agents
US6414154B1 (en) 1998-05-20 2002-07-02 Smithkline Beecham P.L.C. Tetraisoquinoline derivatives as modulators of dopamine D3 receptors
US6060488A (en) * 1998-09-22 2000-05-09 Eli Lilly And Company Benzothiophenes for treating estrogen deficiency
US6605607B1 (en) 1998-10-08 2003-08-12 Smithkline Beecham P.L.C. Tetrahydrobenzazepine derivatives useful as modulators of dopamine D3 receptors (antipsychotic agents)
WO2000023424A1 (en) * 1998-10-20 2000-04-27 Isis Innovation Limited Epibatidine analogues as acetylcholine receptor antagonists
US6133262A (en) * 1998-10-28 2000-10-17 Eli Lilly And Company Antithrombotic agents
US6849656B1 (en) 1999-09-17 2005-02-01 Baylor University Indole-containing and combretastatin-related anti-mitotic and anti-tubulin polymerization agents
US6770643B2 (en) 1999-12-24 2004-08-03 Aventis Pharma Limited Azaindoles
EP1283209A4 (en) * 2000-05-18 2003-07-09 Daiichi Seiyaku Co Novel benzothiophene derivatives
EP1283209A1 (en) * 2000-05-18 2003-02-12 Daiichi Pharmaceutical Co., Ltd. Novel benzothiophene derivatives
CZ304003B6 (en) * 2000-08-23 2013-08-14 Sanofi-Aventis Benzofuran and benzothiophene derivatives, process of their preparation, medicament and pharmaceutical or veterinary compositions in which the derivatives are comprised as well as the use of the derivative for the preparation of a medicament
FR2813306A1 (en) * 2000-08-23 2002-03-01 Sanofi Synthelabo AMINOALKYBENZOYL-BENZOFURANS OR BENZOTHIOPHENES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
US7148240B2 (en) 2000-08-23 2006-12-12 Sanofi-Aventis Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
FR2813308A1 (en) * 2000-08-23 2002-03-01 Sanofi Synthelabo AMINOALKOXYBENZOYL-BENZOFURANS OR BENZOTHIOPHENES, PROCESS FOR THEIR PREPARATION AND COMPOSITIONS CONTAINING SAME
AU2001284149B2 (en) * 2000-08-23 2006-09-21 Sanofi-Aventis Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
WO2002016339A1 (en) * 2000-08-23 2002-02-28 Sanofi-Synthelabo Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
WO2002016340A1 (en) * 2000-08-23 2002-02-28 Sanofi-Synthelabo Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
KR100911280B1 (en) * 2000-08-23 2009-08-11 사노피-아벤티스 Aminoalkylbenzoyl-benzofuran or benzothiophene derivatives, method for preparing same and compositions containing same
US6949583B2 (en) 2000-08-23 2005-09-27 Sanofi-Synthelabo Aminoalkoxybenzoyl-benzofuran or benzothiophene derivatives, method of preparing same and compositions containing same
US6962928B2 (en) 2001-05-22 2005-11-08 Eli Lilly And Company Tetrahydroquinoline derivatives for the inhibition of osteoporosis, estrogen dependent breast cancer, endometriosis and uterine fibrosis
US7056931B2 (en) 2001-05-22 2006-06-06 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US6800654B2 (en) 2001-06-20 2004-10-05 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US6939886B2 (en) 2001-06-20 2005-09-06 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor Type-1 (PAI-1)
US7629377B2 (en) 2001-06-20 2009-12-08 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7074817B2 (en) 2001-06-20 2006-07-11 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7351730B2 (en) 2001-06-20 2008-04-01 Wyeth Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
US7368471B2 (en) 2001-06-20 2008-05-06 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US6599925B2 (en) 2001-06-20 2003-07-29 Wyeth Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7943616B2 (en) 2001-06-21 2011-05-17 Aventis Pharmaceuticals Inc. Azaindoles for inhibiting aurora2 and other kinases
US6897207B2 (en) 2001-06-21 2005-05-24 Aventis Pharmaceuticals Inc. Azaindoles
WO2004000314A1 (en) * 2002-06-21 2003-12-31 Qlt Inc. Methods of using benzothiophenone derivatives to treat cancer or inflammation
US7399867B2 (en) 2002-07-22 2008-07-15 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
US7585977B2 (en) 2002-07-22 2009-09-08 Eli Lilly And Company Selective estrogen receptor modulators containing a phenylsulfonyl group
US7105542B2 (en) * 2002-08-02 2006-09-12 The Ohio State University Research Foundation 2-Heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer
US7829557B2 (en) 2002-08-02 2010-11-09 The Ohio State University Research Foundation 2-heterosubstituted 3-aryl-4H-1-benzopyran-4-ones as novel therapeutics in breast cancer
US7427616B2 (en) 2002-08-06 2008-09-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (TEK) activity
US7160918B2 (en) 2002-12-10 2007-01-09 Hassan Mahmoud Elokdah Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor (PAI-1)
US7459478B2 (en) 2002-12-10 2008-12-02 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7259182B2 (en) 2002-12-10 2007-08-21 Wyeth Aryl, aryloxy, and aklyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7674818B2 (en) 2002-12-10 2010-03-09 Wyeth Llc Aryl, aryloxy, alkyloxy substituted 1H-indol-3-yl glyoxylic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7056943B2 (en) 2002-12-10 2006-06-06 Wyeth Substituted indole oxo-acetyl amino acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7078429B2 (en) 2002-12-10 2006-07-18 Wyeth Substituted 3-carbonyl-1H-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7101903B2 (en) 2002-12-10 2006-09-05 Wyeth Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1)
US7348351B2 (en) 2002-12-10 2008-03-25 Wyeth Substituted 3-alkyl and 3-arylalkyl 1H-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
US7566791B2 (en) 2002-12-10 2009-07-28 Wyeth Substituted 3-carbonyl-1h-indol-1yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
WO2005000834A1 (en) * 2003-06-10 2005-01-06 Eli Lilly And Company Pentafluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
US7462647B2 (en) 2003-06-10 2008-12-09 Eli Lilly And Company Pentalfluoroalkanesulfinyl naphthalenes and related estrogen receptor modulators
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7342039B2 (en) 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7420083B2 (en) 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7803835B2 (en) 2003-09-25 2010-09-28 Wyeth Llc Substituted acetic acid derivatives
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
EP2428516A1 (en) 2003-11-19 2012-03-14 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US9283226B2 (en) 2003-12-23 2016-03-15 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US8691806B2 (en) 2003-12-23 2014-04-08 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
WO2005073206A1 (en) * 2004-01-22 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
WO2005073190A1 (en) * 2004-01-29 2005-08-11 Eli Lilly And Company Selective estrogen receptor modulators
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
US7605172B2 (en) 2004-08-23 2009-10-20 Wyeth Thiazolo-naphthyl acids
US7754747B2 (en) 2004-08-23 2010-07-13 Wyeth Llc Oxazolo-naphthyl acids
US7446121B2 (en) 2004-11-23 2008-11-04 Pfizer Inc. Pyrazole-based HMG CoA reductase inhibitors
US7323483B2 (en) 2005-01-27 2008-01-29 Wyeth Processes and compounds for the preparation of substituted naphthylindole derivatives
GR20050100282A (en) * 2005-06-08 2007-01-19 Αλεξης Μιχαηλ Tissue-specific antiestrogens specific for estrogen receptor
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
US8541461B2 (en) 2005-06-23 2013-09-24 Astex Therapeutics Limited Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
US7683091B2 (en) 2005-08-17 2010-03-23 Wyeth Substituted indoles and methods of their use
EP2392567A1 (en) 2005-10-21 2011-12-07 Bristol-Myers Squibb Company Benzothiazine derivatives and their use as lxr modulators
WO2007062314A2 (en) 2005-11-23 2007-05-31 Bristol-Myers Squibb Company Heterocyclic cetp inhibitors
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
US8497294B2 (en) 2007-03-14 2013-07-30 Astex Therapeutics Limited Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases
EP2826475A1 (en) 2007-10-16 2015-01-21 Repros Therapeutics Inc. Trans-clomiphene for treating diabetes in hypogonadal men
WO2010040274A1 (en) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 Novel dopamine d3 receptor ligands, the preparation and use thereof
US8829001B2 (en) 2008-10-10 2014-09-09 The Institute of Pharmacology and Toxicology Academy of Military Medical Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
WO2013130832A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US10160752B2 (en) * 2012-10-24 2018-12-25 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US10888545B2 (en) 2012-10-24 2021-01-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US10464930B2 (en) 2012-10-24 2019-11-05 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating estrogen-related medical disorders
US9321746B2 (en) 2013-02-19 2016-04-26 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US9931317B2 (en) 2013-02-19 2018-04-03 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US10058534B2 (en) 2013-02-19 2018-08-28 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US9561211B2 (en) 2013-02-19 2017-02-07 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
US8877801B2 (en) 2013-02-19 2014-11-04 Novartis Ag Compounds and compositions as selective estrogen receptor degraders
WO2017081171A1 (en) 2015-11-10 2017-05-18 Paracrine Therapeutics Ab Treatment of er-negative breast cancer with an pdgf-cc inhibitor and an anti estrogen
US11439649B2 (en) 2018-02-21 2022-09-13 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
US11957688B2 (en) 2018-02-21 2024-04-16 OrphAl Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
US20210260052A1 (en) * 2018-07-12 2021-08-26 Eli Lilly And Company Selective estrogen receptor degraders

Also Published As

Publication number Publication date
HU9600947D0 (en) 1996-06-28
CO4290353A1 (en) 1996-04-17
CZ105696A3 (en) 1997-01-15
NZ271733A (en) 1997-11-24
EP0723537A1 (en) 1996-07-31
AU7545394A (en) 1995-05-04
US6756388B1 (en) 2004-06-29
NO961432L (en) 1996-04-11
CA2173243A1 (en) 1995-04-20
BR9407790A (en) 1997-03-18
NO961432D0 (en) 1996-04-11
FI944771A (en) 1995-04-13
ZA947911B (en) 1996-04-11
HUT75231A (en) 1997-04-28
KR960704874A (en) 1996-10-09
CN1133040A (en) 1996-10-09
IL111187A0 (en) 1994-12-29
FI944771A0 (en) 1994-10-11
PE22095A1 (en) 1995-08-15
JPH08511273A (en) 1996-11-26
PL313905A1 (en) 1996-08-05

Similar Documents

Publication Publication Date Title
US6756388B1 (en) Benzothiophenes and related compounds as estrogen agonists
FI116525B (en) Estrogen agonists / antagonists, pharmaceutical compositions containing them, their use and intermediate
CA2123514C (en) Novel benzothiophene derivative
US4418068A (en) Antiestrogenic and antiandrugenic benzothiophenes
JPH06507615A (en) 2-phenylbenzo[b]furan and -thiophene, their production process and pharmaceutical preparations containing the compounds with anti-estrogenic action
PL182493B1 (en) Novel derivatives of bezothiophene, method of obtaining them, novel intermediate compounds and pharmaceutical agent
US20070111988A1 (en) Selective estrogen receptor modulators
JPH10204082A (en) Substituted benzo (b) thiophene compound having activity as selective estrogen preceptor modulator
JP2002538141A (en) N-substituted benzoylindoles as estrogenic agents
US20070066595A1 (en) Selective estrogen receptor modulators
JP5548205B2 (en) Selective estrogen receptor modulator
JPH10109985A (en) Benzo(b)indeno(2,1-d) thiophene compound, its intermediate, its production, its composition, and its using method
JPH10130261A (en) Benzothiophene compound, intermediate, composition and method
EP1551822B1 (en) Pentacyclic oxepines and derivatives thereof, process for their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94193755.0

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AU BR CA CN CZ HU JP KR NO NZ PL RU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994925597

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2173243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 271733

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PV1996-1056

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 08628605

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1994925597

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV1996-1056

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: PV1996-1056

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1994925597

Country of ref document: EP